Unnamed: 0,title,date,stock,sentiment
8919.0,AbbVie And Genmab Announce Broad Oncology Collaboration; AbbVie To Pay Genmab $750M Up Front As Well As Potential Milestones Of Up To $3.15B,2020-06-10 06:01:00-04:00,ABBV,positive
8920.0,AbbVie On Saturday Presents Data Showing RINVOQ Met Its Primary and Key Secondary Endpoints in Phase 3 Head-to-Head Study Versus ORENCIA in Rheumatoid Arthritis Patients,2020-06-08 08:24:00-04:00,ABBV,neutral
8921.0,AbbVie Highlights Presentation Of New Long-Term Data From RINVOQ Phase 3 Studies At 2020 Annual European E-Congress Of Rheumatology,2020-06-04 08:33:00-04:00,ABBV,neutral
8922.0,"Argus Research Upgrades AbbVie to Buy, Announces $115 Price Target",2020-06-02 09:33:00-04:00,ABBV,neutral
8923.0,"AbbVie Reports Submission Of Regulatory Applications To FDA, EMA For RINVOQ For Treatment Of Adults With Active Psoriatic Arthritis",2020-06-01 11:42:00-04:00,ABBV,positive
8924.0,AbbVie and Jacobio Earlier Announced a Strategic Collaboration to Advance SHP2 Inhibitors,2020-06-01 09:09:00-04:00,ABBV,negative
8925.0,AbbVie Presents New Data at the European E-Congress of Rheumatology (EULAR) 2020 Showcasing Depth of its Rheumatology Portfolio,2020-05-27 08:34:00-04:00,ABBV,neutral
8926.0,"Ironwood And AbbVie Report Phase II Trial Of MD-7246 Did Not Achieve Statistically Significant Improvements In Abdominal Pain Relative To Placebo, Companies Plan To Discontinue Development",2020-05-27 08:14:00-04:00,ABBV,negative
8927.0,Synlogic Terminates Collaboration Deal With AbbVie,2020-05-21 06:02:00-04:00,ABBV,neutral
8928.0,"B of A Securities Reinstates Neutral on AbbVie, Announces $95 Price Target",2020-05-18 08:43:00-04:00,ABBV,positive
8929.0,AbbVie Shares Rebound From Session Low As CEO Recently Spoke With Jim Cramer On CNBC's Squawk Street,2020-05-14 09:44:00-04:00,ABBV,neutral
8930.0,AbbVie shares are trading higher JP Morgan upgraded the stock from Neutral to Overweight.,2020-05-12 10:32:00-04:00,ABBV,positive
8931.0,JP Morgan Upgrades AbbVie to Overweight,2020-05-12 10:25:00-04:00,ABBV,neutral
8932.0,"UPDATE: Morgan Stanley On Abbvie Notes 'This is an earnings and multiple call, and we see a positive risk-reward skew given ABBV's 5.6% dividend yield'",2020-05-11 11:45:00-04:00,ABBV,positive
8933.0,"UPDATE: Morgan Stanley Reinstates Abbvie With Overweight, $95 Target Notes 'We view Humira erosion fears as overly discounted and Abbvie's prospects as underappreciated'",2020-05-11 11:45:00-04:00,ABBV,negative
8934.0,"Morgan Stanley Reinstates Overweight on AbbVie, Announces $95 Price Target",2020-05-11 08:37:00-04:00,ABBV,negative
8935.0,"SVB Leerink Maintains Outperform on AbbVie, Raises Price Target to $122",2020-05-11 06:40:00-04:00,ABBV,neutral
8936.0,"AbbVie, Allergan Report FTC Clearance For Deal",2020-05-05 17:52:00-04:00,ABBV,neutral
8937.0,"Abbvie Purchase Of Allergan FTC Approval Is Imminent, Mlex Says",2020-05-05 15:03:00-04:00,ABBV,positive
8938.0,AbbVie shares are trading higher after the company received Health Canada approval for the combination of VENCLEXTA with Obinutuzumab for patients with previously untreated chronic lymphocytic leukemia.,2020-05-05 12:36:00-04:00,ABBV,positive
8939.0,AbbVie Receives Health Canada Approval For The Combination Of VENCLEXTA With Obinutuzumab For Patients With Previously Untreated Chronic Lymphocytic Leukemia,2020-05-05 07:04:00-04:00,ABBV,positive
8940.0,"SVB Leerink Maintains Outperform on AbbVie, Raises Price Target to $107",2020-05-04 06:30:00-04:00,ABBV,neutral
8941.0,From AbbVie Earnings Conference Call: Sees FY20 US Humira Sales Up ~7%,2020-05-01 10:08:00-04:00,ABBV,neutral
8942.0,AbbVie Reaffirms FY20 Standalone Adj. EPS Guidance $9.61-$9.71,2020-05-01 07:46:00-04:00,ABBV,neutral
8943.0,"AbbVie Q1 Adj. EPS $2.420 Beats $2.250 Estimate, Sales $8.619B Beat $8.330B Estimate",2020-05-01 07:46:00-04:00,ABBV,neutral
8944.0,"Harpoon Therapeutics Doses First Patient with HPN217, a BCMA Targeting TriTAC, for Multiple Myeloma, Triggering a $50M Milestone Payment from AbbVie",2020-04-27 06:31:00-04:00,ABBV,neutral
8945.0,FDA Says Expanded The Indication Of Ibrutinib (Imbruvica),2020-04-21 14:55:00-04:00,ABBV,neutral
8946.0,"Shares of several healthcare companies are trading lower with the overall market on continued downward momentum after oil prices fell to historic lows, partially stemming from weak demand caused by the coronavirus pandemic.",2020-04-21 11:35:00-04:00,ABBV,negative
8947.0,"RBC Capital Upgrades AbbVie to Outperform, Raises Price Target to $93",2020-04-20 07:01:00-04:00,ABBV,neutral
8948.0,"UBS Maintains Buy on AbbVie, Lowers Price Target to $96",2020-04-13 09:44:00-04:00,ABBV,negative
8949.0,"Shares of several healthcare companies are trading higher amid market strength. NOTE: The coronavirus pandemic has potentially benefited the sector due to demand for medical supplies, testing and treatment candidates",2020-03-31 12:00:00-04:00,ABBV,positive
8950.0,AbbVie's Phase 3 Trial of VENCLEXTA in Combination with Azacitidine for Treatment of Acute Myeloid Leukemia Met its Dual Primary Endpoints,2020-03-23 08:22:00-04:00,ABBV,neutral
8951.0,Societe Generale Downgrades AbbVie to Hold,2020-03-23 05:57:00-04:00,ABBV,neutral
8952.0,"AbbVie, Allergan Report Signing Of Consent Decree Deal With FTC Staff Related To Deal",2020-03-17 16:31:00-04:00,ABBV,positive
8953.0,AbbVie Reports European Commission Approval Of VENCLYXTO Combo Regimen For Patients With Previously-Untreated Chronic Lymphocytic Leukemia,2020-03-12 07:00:00-04:00,ABBV,positive
8954.0,"Abbvie Announces New Formulary Listings For Skyrizi In The Treatment Of Moderate To Severe Plaque Psoriasis; Manitoba Lists Skyrizi On Its Provincial Formulary Effective Mar 02, Non-Insured Health Benefits Program Lists Skyrizi On Its Formulary",2020-03-11 13:10:00-04:00,ABBV,positive
8955.0,Abbvie Says Partnering With Global Authorities To Determine Efficacy Of HIV Drug In Treating COVID-19,2020-03-09 08:47:00-04:00,ABBV,neutral
8956.0,Bristol Myers' Phase 3 Trial of Empliciti in Untreated Multiple Myeloma Did Not Meet its Primary Endpoint,2020-03-09 07:02:00-04:00,ABBV,neutral
8957.0,"AbbVie, Allergan Receive Final Europan Approval To Close Deal",2020-03-03 08:03:00-05:00,ABBV,positive
8958.0,AbbVie Earlier Reported Results From Phase 3 Study Evaluating VENCLEXTA Did Not Meet Primary Endpoint Of Statistically Significant Improvement Of Overall Survival For Patients With Acute Myeloid Leukemia,2020-03-02 09:08:00-05:00,ABBV,positive
8959.0,"Barclays Initiates Coverage On AbbVie with Equal-Weight Rating, Announces $97 Price Target",2020-02-27 07:55:00-05:00,ABBV,neutral
8960.0,"AbbVie to Present at the Cowen 40th Annual Health Care Conference On March 4, 2020",2020-02-19 08:17:00-05:00,ABBV,positive
8961.0,"Cowen & Co. Maintains Outperform on AbbVie, Raises Price Target to $105",2020-02-18 07:44:00-05:00,ABBV,neutral
8962.0,AbbVie shares are trading higher after Mizuho maintained a Buy rating on the stock and raised its price target from $96 to $104.,2020-02-10 10:23:00-05:00,ABBV,positive
8963.0,"Mizuho Maintains Buy on AbbVie, Raises Price Target to $104",2020-02-10 07:25:00-05:00,ABBV,neutral
8964.0,From AbbVie Earnings Conference Call: CFO Sees US Humira Sales Up 9% This Year,2020-02-07 09:39:00-05:00,ABBV,neutral
8965.0,"From AbbVie Earnings Conference Call: Commercial Access For RINVOQ At 95+%, For SKYRIZI At Parity To Humira, 95+%",2020-02-07 09:09:00-05:00,ABBV,neutral
8966.0,AbbVie shares are trading higher after the company reported better-than-expected Q4 EPS and sales results. The company also issued FY20 EPS guidance above analyst estimates and sales growth of ~8%.,2020-02-07 07:52:00-05:00,ABBV,positive
8967.0,"AbbVie Sees FY20 Adj. EPS $9.61-$9.71 vs $9.48 Estimate, Sales Growth ~8%",2020-02-07 07:46:00-05:00,ABBV,positive
8968.0,"AbbVie Q4 EPS $2.21 Beats $2.19 Estimate, Sales $8.704B Beat $8.7B Estimate",2020-02-07 07:45:00-05:00,ABBV,neutral
8969.0,"UPDATE: Mizuho Initiates Coverage On AbbVie with Buy Rating, Announces $96 Price Target As Firm Notes The 'Allergan Acquisition Brings In Multiple New Growth Drivers and Helps Mitigate Humira Erosion.'",2020-02-06 11:25:00-05:00,ABBV,positive
8970.0,"Mizuho Initiates Coverage On AbbVie with Buy Rating, Announces $96 Price Target",2020-02-06 05:10:00-05:00,ABBV,neutral
8971.0,"Mizuho Initiates AbbVie, Biohaven With Buy Ratings, Eli Lilly, Alkermes With Neutral Ratings",2020-02-05 16:42:00-05:00,ABBV,neutral
8972.0,AbbVie Announces RINVOQ Met Primary And Key Secondary Endpoints In Phase 3 Study In Psoriatic Arthritis,2020-02-05 08:45:00-05:00,ABBV,neutral
8973.0,"AbbVie Reports Receives Positive CHMP Opinion For Maviret For Chronic Hep C, Compensated Cirrhosis",2020-01-31 07:16:00-05:00,ABBV,positive
8974.0,AbbVie Reports Receives Positive CHMP Opinion For VENCLYXTO For Chemo-Free Combo Regimen For Patients With Previously-Untreated Chronic Lymphocytic Leukemia,2020-01-31 06:59:00-05:00,ABBV,positive
8975.0,AbbVie shares are trading higher after the company announced Allergan entered into definitive agreements to divest brazikumab and Zenpep. The agreements are apart of the approval process for AbbVie's acquisition of Allergan.,2020-01-27 09:57:00-05:00,ABBV,positive
8976.0,"'China testing HIV drug as treatment for new coronavirus, AbbVie says' -Reuters",2020-01-27 08:09:00-05:00,ABBV,neutral
8977.0,From JP Morgan Healthcare Conference: AbbVie CEO Sees 7-8 US Competitors To Humira In 2023,2020-01-15 11:07:00-05:00,ABBV,positive
8978.0,From JP Morgan Healthcare Conference: AbbVie CEO Sees Humira Sales Starting To Slow Heading Into FY22,2020-01-15 11:03:00-05:00,ABBV,positive
8979.0,From JP Morgan Healthcare Conference: AbbVie CEO Sees Humira Continuing To Grow In US Through The Time It Loses Market Exclusivity,2020-01-15 10:48:00-05:00,ABBV,positive
8980.0,Abbvie's SKYRIZI Met Barth Primary And All Ranked Secondary Endpoints In Phase 3 Study,2020-01-14 08:48:00-05:00,ABBV,neutral
8981.0,"EU Commission Approves Abbvie's Acquisition Of Allergan, Subject To Conditions",2020-01-10 09:11:00-05:00,ABBV,positive
8982.0,"AbbVie Receives Health Canada Approval Of RINVOQ, An Oral Medication For Treatment Of Adults With Moderate To Severe Active Rheumatoid Arthritis",2020-01-07 08:05:00-05:00,ABBV,positive
8983.0,"Cowen & Co. Maintains Outperform on AbbVie, Raises Price Target to $98",2019-12-26 08:27:00-05:00,ABBV,neutral
8984.0,AbbVie shares are trading higher. Not seeing any news to justify the price action.,2019-12-20 11:44:00-05:00,ABBV,positive
8985.0,Abbvie Reaches An Agreement With The Pan-Canadian Pharmaceutical Alliance For The Combination Venclexta With Rituximab As A Treatment For Patients With Chronic Lymphocytic Leukemia,2019-12-18 14:58:00-05:00,ABBV,positive
8986.0,AbbVie Receives European Commission Approval Of RINVOQ For The Treatment Of Adults With Moderate To Severe Active Rheumatoid Arthritis,2019-12-18 10:56:00-05:00,ABBV,positive
8987.0,Watching Allergan Shares AS Hearing Co. Deal With AbbVie To Receive US Regulatory Approval In Jan. 2020,2019-12-13 09:44:00-05:00,ABBV,positive
8988.0,AbbVie and Scripps Research to Collaborate on New Therapies,2019-12-09 08:13:00-05:00,ABBV,neutral
8989.0,AbbVie Reports Deal With Pan-Canadian Pharma Alliance For Skyrizi For Treatment Of Moderate To Severe Plaque Psoriasis,2019-12-06 06:10:00-05:00,ABBV,negative
8990.0,U.S. Considers Scaling Back IP Protections For Big Drugmakers To Help Win Democratic Support For New Trade Pact With Mexico And Canada,2019-12-02 16:09:00-05:00,ABBV,positive
8991.0,"Trump Says he Will Release a Plan to Let States Import Prescription Drugs Which are ""MUCH CHEAPER""",2019-11-22 14:08:00-05:00,ABBV,neutral
8992.0,"Citi Maintains Buy on AbbVie, Raises Price Target to $98",2019-11-20 09:16:00-05:00,ABBV,neutral
8993.0,Dragonfly Therapeutics Announces Collaboration With AbbVie For Autoimmune Diseases and Oncology,2019-11-20 08:01:00-05:00,ABBV,neutral
8994.0,"UBS Maintains Buy on AbbVie, Raises Price Target to $96",2019-11-19 07:16:00-05:00,ABBV,neutral
8995.0,AbbVie shares are trading higher after the company announced its Phase 2/3 SELECT-AXIS1 trial in which twice as many adult patients with active ankylosing spondylitis treated with RINVOQ achieved the primary endpoint.,2019-11-12 11:29:00-05:00,ABBV,positive
8996.0,Abbvie Presents Data Showing RINVOQ Met Its Primary Endpoint,2019-11-12 11:17:00-05:00,ABBV,neutral
8997.0,AbbVie shares are trading higher. The company submitted a Supplemental New Drug Application For IMBRUVICA. The company is also looking to raise as much as $28 billion to fund its Allergan takeover.,2019-11-08 11:02:00-05:00,ABBV,positive
8998.0,AbbVie Reports Submission Of Supplemental New Drug Application For IMBRUVICA,2019-11-08 07:54:00-05:00,ABBV,neutral
8999.0,AbbVie Announces Launch Of Private Offering Of Senior Unsecured Notes; Terms Not Disclosed,2019-11-06 15:07:00-05:00,ABBV,negative
9000.0,Allergan And Abbvie Continue To Expect To Close The Transaction In Early 2020,2019-11-05 07:16:00-05:00,ABBV,neutral
9001.0,AbbVie shares are trading higher after the company reported better-than-expected Q3 EPS and sales results. The company also raised its FY19 EPS guidance above analyst estimates.,2019-11-01 11:18:00-04:00,ABBV,positive
9002.0,From AbbVie Earnings Conference Call: Co. Notified FTC It Plans To Divest 2 Assets For Allergan Deal To Go Through,2019-11-01 09:37:00-04:00,ABBV,positive
9003.0,Abbvie Sees 2019 Revenue Growth Of 2.5% On Operational Basis,2019-11-01 09:26:00-04:00,ABBV,positive
9004.0,Abbvie Says Launch Of Psoriasis Drug Skyrizi 'Is Going Extremely Well' And Commercial Access For The Drug Is At More Than 80%,2019-11-01 09:13:00-04:00,ABBV,positive
9005.0,"AbbVie Narrows, Raises Lower End Of FY19 Adj. EPS Guidance From $8.82-$8.92 To $8.90-$8.92 vs $8.90 Estimate",2019-11-01 07:48:00-04:00,ABBV,negative
9006.0,"AbbVie Q3 Adj. EPS $2.33 Beats $2.3 Estimate, Sales $8.479B Beat $8.38B Estimate",2019-11-01 07:47:00-04:00,ABBV,neutral
9007.0,Abbvie's RINVOQ Meets Primary And All Ranked Secondary Endpoints In Phase 3 Study In Psoriatic Arthritis,2019-10-31 08:48:00-04:00,ABBV,neutral
9008.0,Allergan Reports Shareholders Have Approved Deal By AbbVie,2019-10-14 09:16:00-04:00,ABBV,positive
9009.0,AbbVie shares trading lower with the broader stock market following concerning ISM manufacturing data. Not seeing any company-specific news to justify the move lower.,2019-10-01 13:31:00-04:00,ABBV,negative
9010.0,Abbvie Inc Co And Allergan Are Cooperating Fully With FTC And Continue To Expect To Close Transaction In Early 2020,2019-09-27 16:15:00-04:00,ABBV,neutral
9011.0,AbbVie shares are trading higher after Citigroup upgraded the stock from Neutral to Buy.,2019-09-26 10:00:00-04:00,ABBV,positive
9012.0,Citigroup Upgrades AbbVie to Buy,2019-09-26 06:33:00-04:00,ABBV,neutral
9013.0,Shares of several drug companies are trading higher after Senate Majority Leader McConnell suggested a new Democratic drug price reform proposal would be dead on arrival.,2019-09-20 13:00:00-04:00,ABBV,negative
9014.0,UPDATE: UBS On AbbVie Also Notes 'Post '23 we estimate stable cash flows driven by ABBV's 5 key growth assets & AGN Aesthetics franchise. NEWCO cash flows are immediately tangible via a sustainable & growing dividend',2019-09-12 10:30:00-04:00,ABBV,positive
9015.0,"UPDATE: UBS Upgrades AbbVie To Buy, Lowers Target To $79 As Firm Notes Co's 'acquisition of AGN leads to a NEWCO generating $20B+ of annual free cash flow growing to a highly compelling, 9% FCF yield in '23E (year of Humira's US patent expiry)'",2019-09-12 10:30:00-04:00,ABBV,positive
9016.0,AbbVie shares are trading higher after UBS upgraded the stock from Neutral to Buy.,2019-09-12 09:18:00-04:00,ABBV,positive
9017.0,"UBS Upgrades AbbVie to Buy, Lowers Price Target to $79",2019-09-12 06:53:00-04:00,ABBV,negative
9018.0,Idera Pharmaceuticals Announces Immuno-Oncology Clinical Research Collaboration With AbbVie,2019-09-04 07:03:00-04:00,ABBV,neutral
9019.0,"Piper Jaffray Maintains Overweight on AbbVie, Raises Price Target to $81",2019-09-04 06:27:00-04:00,ABBV,negative
9020.0,AbbVie Says its Phase 3 Trial Evaluating Rova-T Demonstrated 'No Survival Benefit',2019-08-29 08:48:00-04:00,ABBV,positive
9021.0,AbbVie to Discontinue Development of Rovalpituzumab Tesirine (Rova-T),2019-08-29 08:47:00-04:00,ABBV,neutral
9022.0,"UPDATE: PiperJaffray On AbbVie Also Notes 'while we have been rather vocal about the various pressure points on the Humira business, we do think ABBV has a great opportunity to pivot the narrative towards successful launches of Skyrizi and now Rinvoq'",2019-08-20 10:30:00-04:00,ABBV,positive
9023.0,"UPDATE: PiperJaffray Upgrades AbbVie To Overweight, Announces $80 Target As Firm Notes 'we do think a bottom of sorts has been found on this name with the stock around ~$66'",2019-08-20 10:30:00-04:00,ABBV,negative
9024.0,AbbVie shares are trading higher after Piper Jaffray upgraded the stock from Neutral to Overweight and announced a price target of $80 per share.,2019-08-20 08:17:00-04:00,ABBV,positive
9025.0,"Piper Jaffray Upgrades AbbVie to Overweight, Announces $80 Price Target",2019-08-20 06:48:00-04:00,ABBV,negative
9026.0,"Shares of healthcare companies are trading higher as US markets rebound from recent weakness following a yield curve inversion, which caused recession fears. Trump also recently announced the US would delay China tariffs, renewing hopes of a trade deal.",2019-08-16 13:27:00-04:00,ABBV,negative
9027.0,FDA Approves Nda For Abbvie's Rinvoq (Upadacitinib) For Treatment Of Rheumatoid Arthritis,2019-08-16 12:25:00-04:00,ABBV,positive
9028.0,AbbVie Shares Tick Slightly Lower As Hearing Co. Accused Of Scheming To Stretch Androgel Monopoly,2019-08-07 10:45:00-04:00,ABBV,negative
9029.0,AbbVie Submits New Drug Application FDA For Investigational Elagolix For Management Of Heavy Menstrual Bleeding Associated With Uterine Fibroids In Women,2019-08-05 08:35:00-04:00,ABBV,neutral
9030.0,Enanta's HCV Collaboration Partner AbbVie Receives Approval By European Commission For MAVIRET To Shorten Treatment Duration To Eight Weeks For Treatment-Naïve HCV Patients With Compensated Cirrhosis,2019-08-02 08:54:00-04:00,ABBV,positive
9031.0,From AbbVie Q2 Earnings Conference Call: Raises FY19 Sales Growth Guidance From ~1% To ~2%,2019-07-26 09:27:00-04:00,ABBV,positive
9032.0,Abbvie CEO Says Co Remains 'Well Positioned' To Deliver Double-Digit Earnings Growth In 2019,2019-07-26 09:15:00-04:00,ABBV,positive
9033.0,AbbVie shares are trading higher after the company reported better-than-expected Q2 EPS and sales results. The company also raised its FY19 EPS guidance above analyst estimates.,2019-07-26 08:45:00-04:00,ABBV,positive
9034.0,UPDATE: AbbVie Raises FY19 Adj EPS Guidance From $8.73-$8.83 To $8.82-$8.92 vs $8.82 Estimate,2019-07-26 07:43:00-04:00,ABBV,neutral
9035.0,AbbVie Raises FY19 Guidance,2019-07-26 07:43:00-04:00,ABBV,neutral
9036.0,"AbbVie Q2 Adj. EPS $2.26 Beats $2.2 Estimate, Sales $8.255B Beat $8.1B Estimate",2019-07-26 07:43:00-04:00,ABBV,neutral
9037.0,AbbVie Acquires Mavupharma; Terms Not Disclosed,2019-07-15 08:01:00-04:00,ABBV,neutral
9038.0,"CytomX Therapeutics Announces Second Target Selection And Program Initiation With AbbVie Under Ongoing, Multi-Program Strategic Oncology Collaboration",2019-07-09 08:04:00-04:00,ABBV,neutral
9039.0,"Shares of several healthcare companies are trading lower after Trump on Friday said he was preparing an executive order declaring a 'favored nations clause' for drug prices, lowering the price that consumers will pay prescription drugs.",2019-07-08 12:55:00-04:00,ABBV,positive
9040.0,AbbVie Shares Tick Higher Over Last Few Mins. Following Mention Of Unusual Option Activity By Jon Najarian On CNBC's 'Fast Money: Halftime Report',2019-06-28 12:54:00-04:00,ABBV,positive
9041.0,AbbVie shares are trading higher as the stock continues to rebound after dipping on Tuesday when the company announced it will acquire Allergan for $60 billion.,2019-06-28 10:10:00-04:00,ABBV,positive
9042.0,AbbVie shares are trading higher as the stock continues to rebound after dipping on Tuesday when the company announced it will acquire Allergan for $60 billion.,2019-06-27 11:14:00-04:00,ABBV,positive
9043.0,"AbbVie shares are trading higher, rebounding after dipping on Monday following the announcement that the company will acquire Allergan for $60 billion. SVB Leerink upgraded the stock from Market Perform to Outperform.",2019-06-26 09:33:00-04:00,ABBV,positive
9044.0,SVB Leerink Upgrades AbbVie to Outperform,2019-06-26 07:24:00-04:00,ABBV,neutral
9045.0,AbbVie Receives Positive Recommendation From INESSS For The Combination VENCLEXTA With Rituximab As A Treatment For Patients With Chronic Lymphocytic Leukemia,2019-06-25 09:21:00-04:00,ABBV,positive
9046.0,AbbVie CEO Says Feels Comfortable With Risk Related To Allergan's Opioid Exposure,2019-06-25 08:58:00-04:00,ABBV,positive
9047.0,Abbvie CEO Says Believes It Is Highly Unlikely There Will Be A Botox Biosimilar For A Long Time,2019-06-25 08:57:00-04:00,ABBV,neutral
9048.0,AbbVie Says Allergan Deal Mitigates Impact Of 2023 US Humira Loss Of Exclusivity,2019-06-25 07:17:00-04:00,ABBV,negative
9049.0,AbbVie shares are trading lower after the company announced it will acquire Allergan for $188.24/share.,2019-06-25 06:47:00-04:00,ABBV,neutral
9050.0,AbbVie To Acquire Allergan For $188.24/Share In Cash And Stock,2019-06-25 06:45:00-04:00,ABBV,neutral
9051.0,"UPDATE: AbbVie Would Pay $188/Share In Cash And Stock For Allergan, Representing 45% Premium To Allergan's Monday Close, According To Sources Cited By WSJ",2019-06-25 06:33:00-04:00,ABBV,negative
9052.0,AbbVie Announces US FDA Lifts Partial Clinical Hold on Phase 3 Study of Venetoclax in Patients with Multiple Myeloma Positive for the t(11;14) Genetic Abnormality,2019-06-24 08:47:00-04:00,ABBV,positive
9053.0,Eli Lilly Presents Data on its Taltz Versus AbbVie's Humira in Patients With Active Psoriatic Arthiritis at the European Congress of Rheumatology,2019-06-14 06:47:00-04:00,ABBV,positive
9054.0,AbbVie Reports To Present New Long-Term Data from Upadacitinib Phase 3 Studies in Rheumatoid Arthritis Including Results on Clinical Remission at 48 Weeks at EULAR,2019-06-12 18:02:00-04:00,ABBV,neutral
9055.0,AbbVie shares are trading higher after the company's SKYRIZI maintained its complete skin clearance.,2019-06-11 11:44:00-04:00,ABBV,positive
9056.0,AbbVie Reports Recommendation From Pan-Canadian Oncology Drug Review Expert Review Committee For Combo VENCLEXTA With Rituxuimab As Treatment For Patients With Chronic Lymphocytic Leukemia,2019-06-06 09:17:00-04:00,ABBV,neutral
9057.0,AbbVie Highlights Publication Of Data From Venetoclax Chemotherapy-Free Combination Regimen For Patients With Previously Untreated Chronic Lymphocytic Leukemia,2019-06-04 11:11:00-04:00,ABBV,neutral
9058.0,AbbVie To Present Results From Several Studies And Clinical Trials Investigating Medicines Across More Than 15 Cancers At The 2019 ASCO And EHA Meetings,2019-05-30 08:46:00-04:00,ABBV,neutral
9059.0,"Goldman Sachs Initiates Coverage On AbbVie with Neutral Rating, Announces $84 Price Target",2019-05-28 07:40:00-04:00,ABBV,neutral
9060.0,"Trader Idea Feed: 'We took a look at the late-stage brain cancer pipeline, after $TOCA news and $ABBV and $BMY failures this month. And found only 5 active pivotal trials. Which includes $NWBO, so arguably only 4. Is $CELG the next big hope?' @ByAmyBrown",2019-05-22 14:14:00-04:00,ABBV,negative
9061.0,AbbVie Reports Study On Depatuxizumab Mafodotin Did Not Meet Primary Endpoint,2019-05-17 08:45:00-04:00,ABBV,neutral
9062.0,MC10 And AbbVie Announce Clinical Trials In Multiple Sclerosis Using The BioStamp nPoint System,2019-05-14 10:14:00-04:00,ABBV,neutral
9063.0,AbbVie shares are trading higher after the company settled its HUMIRA patent litigation with Boehringer Ingelheim.,2019-05-14 09:50:00-04:00,ABBV,positive
9064.0,AbbVie Resolves HUMIRA US Patent Litigation With Boehringer Ingelheim; Co. Will Grant BI A Non-Exclusive License To HUMIRA-Related Intellectual Property In US,2019-05-14 08:35:00-04:00,ABBV,positive
9065.0,European Commission Approves Abbvie's SKYRIZI For Treatment Of Moderate To Severe Plaque Psoriasis,2019-04-30 07:52:00-04:00,ABBV,neutral
9066.0,"AbbVie Highlights Will Present New, Updated Data of Investigational Medicines for Parkinson's Disease and Multiple Sclerosis at 2019 American Academy of Neurology Annual Meeting",2019-04-30 07:26:00-04:00,ABBV,neutral
9067.0,"BMO Capital Upgrades AbbVie Inc. Common Stock to Market Perform, Raises Price Target to $79",2019-04-29 06:19:00-04:00,ABBV,neutral
9068.0,Abbvie Says It Is Industry's Responsibility To Cover Some Drug Costs And Share Them With The Government To Make Them Affordable For Patients,2019-04-25 10:01:00-04:00,ABBV,positive
9069.0,From Abbvie Conference Call; Co. Says Humira Biosimilars From Biogen And Amgen In Europe Have Been The Most Aggressive In The Market So Far,2019-04-25 09:44:00-04:00,ABBV,negative
9070.0,AbbVie  Raises FY19 Adj. EPS Guidance From $8.65-$8.75 To $8.73-$8.83 vs $8.69 Est.,2019-04-25 07:43:00-04:00,ABBV,neutral
9071.0,"AbbVie Q1 Adj. EPS $2.14 Beats $2.05 Estimate, Sales $7.83B Beat $7.76B Estimate",2019-04-25 07:42:00-04:00,ABBV,neutral
9072.0,"Shares of several healthcare stocks are trading higher in a potential rebound from last week's selloff. In an upgrade of HCA Healthcare, Raymond James analysts noted the selloff was 'based on legislation that has almost no chance of passing'",2019-04-23 11:52:00-04:00,ABBV,positive
9073.0,Watching AbbVie Shares As Health Canada Approved Skyrizi For Treatment Of Moderate to Severe Plaque Psoriasis,2019-04-18 10:06:00-04:00,ABBV,positive
9074.0,AbbVie's MAVIRET Now reimbursed In Quebec,2019-04-11 09:02:00-04:00,ABBV,neutral
9075.0,AbbVie Reports New Formulary Listings For Hep C Treatment MAVIRET,2019-04-04 10:01:00-04:00,ABBV,neutral
9076.0,AbbVie shares are trading higher after development partner Alector announced it is initiating a phase 1 trial to treat Alzheimer's Disease.,2019-04-02 11:50:00-04:00,ABBV,positive
9077.0,Alector Initiates Phase 1 Trial Of AL003 For Treatment Of Patients With Alzheimer's Disease,2019-04-01 16:42:00-04:00,ABBV,neutral
9078.0,"British Columbia, Canada's Pharmacare Lists AbbVie's Maviret On Its Formulary, Effective Mar. 21, 2019",2019-03-22 10:30:00-04:00,ABBV,positive
9079.0,FDA Issues Warning Related To Risks Associated With AbbVie's VENCLEXTA In Multiple Myeloma,2019-03-21 14:40:00-04:00,ABBV,negative
9080.0,UPDATE: AbbVie Says 'remains confident in the benefit/risk profile of venetoclax in those approved indications',2019-03-19 08:49:00-04:00,ABBV,positive
9081.0,"UPDATE: AbbVie Says 'partial clinical hold follows a review of data from the ongoing Phase 3 BELLINI trial (M14-031),a study in relapsed/refractory multiple myeloma,in which a higher proportion of deaths was observed in the venetoclax arm'",2019-03-19 08:48:00-04:00,ABBV,neutral
9082.0,AbbVie Reports FDA Placed Partial Clinical Hold On All Trials Evaluating Venetoclax For Treatment Of Multiple Myeloma,2019-03-19 08:48:00-04:00,ABBV,neutral
9083.0,Principia Biopharma Reacquires Rights To Oral Immunoproteasome Program,2019-03-11 08:01:00-04:00,ABBV,neutral
9084.0,AbbVie Reports FDA Granted Fifth Breakthrough Therapy Designation For Tovenetoclax For Combo Use With Obinutuzumab,2019-03-07 08:47:00-05:00,ABBV,positive
9085.0,AbbVie Reports Received CHMP Position Opinion For SKYRIZI For Treatment Of Moderate To Severe Plaque Psoriasis,2019-03-01 07:14:00-05:00,ABBV,negative
9086.0,Abbvie And Voyager Earlier Announced Parkinson's Collaboration With AbbVie; Voyager Will Receive $65M Upfront And Up To $245M In Preclinical And Phase 1 Option Payments,2019-02-22 09:29:00-05:00,ABBV,neutral
9087.0,Voyager Therapeutics And AbbVie Announce Collaboration To Develop Vectorized Antibodies For Parkinson's Disease And Other Synucleinopathies; Voyager To Receiver $65M Upfront And Up To $245M In Preclinical Phase 1 Option Payments,2019-02-22 08:05:00-05:00,ABBV,neutral
9088.0,"Morgan Stanley Expects A Verdict On Amgen Vs. Sandoz Enbrel IP Litigation In 1Q19; Firm Estimates 'ABBV could be down 6–8% if the ruling is against Amgen, up 1–2% if it's for Amgen, and ~0% if there is a settlement'",2019-02-20 08:40:00-05:00,ABBV,negative
9089.0,AbbVie Reports HUMIRA Approved By Health Canada To Treat Pediatric Patients With Chronic Non-Infectious Anterior Uveitis,2019-02-20 08:06:00-05:00,ABBV,positive
9090.0,AbbVie Reports New Drug Application Accepted For Priority Review By FDA For Upadacitinib For Treatment Of Moderate To Severe Rheumatoid Arthritis,2019-02-19 08:33:00-05:00,ABBV,negative
9091.0,"FDA Commissioner Scott Gottlieb Issues Statement On New Policy To Improve Access, Foster Price Competition For Drugs Which Face Inadequate Generic Competition; FDA To Advance Added Policies To Promote This Over Next Year",2019-02-15 10:21:00-05:00,ABBV,positive
9092.0,"Centers For Medicaid, Medicare Has Proposed Coverage With Evidence Development For CAR-T Therapy, Decision Would Provide Nationwide Consistency In CMS Coverage",2019-02-15 09:01:00-05:00,ABBV,neutral
9093.0,AbbVie to Collaborate with Teneobio to Develop and Commercialize an Immunotherapeutic for the Treatment of Multiple Myeloma,2019-02-11 08:03:00-05:00,ABBV,neutral
9094.0,"Neurocrine Biosciences Sees FY19 Sales Milestones Under AbbVie Deal $20M; Ongoing SG&A, R&D Expenses Expected $550M-$600M",2019-02-05 16:37:00-05:00,ABBV,neutral
9095.0,"Stocks Which Set New 52-Week Low Mon., Jan. 28, 2019",2019-01-28 15:33:00-05:00,ABBV,negative
9096.0,Abbvie shares are continuing lower following a large sell off Friday due to worse than expected Q4 EPS and revenue results.,2019-01-28 11:36:00-05:00,ABBV,negative
9097.0,AbbVie Announces FDA Approval of IMBRUVICA Plus Obinutuzumab for Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma in Previously Untreated Patien,2019-01-28 07:08:00-05:00,ABBV,positive
9098.0,From AbbVie Q4 Earnings Conference Call: CEO Richard Gonzalez Says Rumors Of His Retirement Are False,2019-01-25 09:40:00-05:00,ABBV,neutral
9099.0,"From AbbVie Q4 Earnings Conference Call: Sees Q1 EPS $2.05-$2.07 vs $2.03 Estimate, Sales $7.7B vs $8B Est.",2019-01-25 09:40:00-05:00,ABBV,neutral
9100.0,AbbVie shares are trading lower after the company missed Q4 EPS and sales estimates.,2019-01-25 09:37:00-05:00,ABBV,negative
9101.0,"From AbbVie Conference Call; Co. Says Humira Will Continue To Generate 'Strong Revenue', Driving Roughly $1B Of Growth In 2019",2019-01-25 09:09:00-05:00,ABBV,positive
9102.0,"UPDATE: Coherus Says License Period In US Begins Dec. 15, 2023; Coherus Will Pay Royalties To AbbVie, But Financial Terms Not Disclosed",2019-01-25 08:02:00-05:00,ABBV,negative
9103.0,Coherus BioSciences Reports Global Settlement With AbbVie Which Secures Rights To Commercialize CHS-1420,2019-01-25 08:01:00-05:00,ABBV,positive
9104.0,AbbVie Inc. Sees FY19 Adj. EPS $8.65-$8.75 vs $8.71 Est.,2019-01-25 07:43:00-05:00,ABBV,neutral
9105.0,"UBS Assumes AbbVie at Neutral, Lowers Price Target To $91",2019-01-23 08:17:00-05:00,ABBV,negative
9106.0,AbbVie Announces Phase 3 Study of Ibrutinib In Metastatic Pancreatic Cancer Did Not Meet Primary Endpoint Of Improving Progression-Free Survival,2019-01-18 16:31:00-05:00,ABBV,negative
9107.0,"Stocks Trading Ex Dividend For Mon., Jan. 14, 2019",2019-01-14 09:32:00-05:00,ABBV,neutral
9108.0,"Stocks That Will Be Trading Ex Dividend Mon., Jan. 14, 2019",2019-01-11 12:34:00-05:00,ABBV,neutral
9109.0,"AbbVie Exec Speaking At JP Morgan Healthcare Conference Says Sees Non-Humira Sales Growing To $35B+ In 2025, Sees Mavyret Remaining A Strong Source Of Cash Flow Over Long-Term",2019-01-09 11:05:00-05:00,ABBV,positive
9110.0,AbbVie Reports Strategic Collaboration With Tizona Therapeutics To Develop First-In-Class Immunotherapy For Cancer Targeting CD39,2019-01-03 08:36:00-05:00,ABBV,negative
9111.0,Bank of America Downgrades AbbVie to Neutral,2019-01-03 07:51:00-05:00,ABBV,neutral
9112.0,Standpoint Research Initiates Coverage On AbbVie with Buy Rating,2018-12-26 08:14:00-05:00,ABBV,neutral
9113.0,"AbbVie Announces a Partnership with Lupin to Develop an Oncology Drug, AbbView to Make a $30M Upfront Payment",2018-12-24 09:47:00-05:00,ABBV,neutral
9114.0,AbbVie shares are trading up 3.1% after the company submitted a New Drug Application to the FDA and a Marketing Authorization Application to the EMA for Upadacitinib for Rheumatoid Arthritis.,2018-12-20 15:38:00-05:00,ABBV,positive
9115.0,AbbVie Submits New Drug Application FDA And Marketing Authorization Application To EMA For Upadacitinib For Rheumatoid Arthritis,2018-12-20 08:50:00-05:00,ABBV,neutral
9116.0,AbbVie Announces Executive Leadership Changes,2018-12-17 09:12:00-05:00,ABBV,neutral
9117.0,"Eli Lilly Says Taltz, in a Superiority Study Vs AbbVie's Humira, in Patients with Active Psoriatic Arthritis Met All Primary and Major Secondary Endpoints",2018-12-17 06:47:00-05:00,ABBV,positive
9118.0,AbbVie Adds $5B To Buyback,2018-12-13 13:00:00-05:00,ABBV,neutral
9119.0,AbbVie On Wednesday Announced It Has Halted Its Phase 3 Trial Of Rova-T In Advanced Small-Cell Lung Cancer After An Independent Data Monitoring Committee Recommended Terminating Enrollment,2018-12-06 09:28:00-05:00,ABBV,negative
9120.0,AbbVie Reports IMBRUVICA Phase 3 Combination Data With Obinutuzumab Shows Significant Improvement In Progression-Free Survival Over Standard Chemoimmunotherapy Of Chlorambucil Plus Obinutuzumab In Lymphocytic Leukemia And Small Lymphocytic Lymphoma,2018-12-03 14:21:00-05:00,ABBV,positive
9121.0,AbbVie shares are trading up 3.4% after the company announced a global patent license with Pfizer for HUMIRA; Pfizer shares up 1.3%.,2018-11-30 13:58:00-05:00,ABBV,positive
9122.0,Pfizer Reaches a Global Agreement With AbbVie For Biosimilar To HUMIRA,2018-11-30 10:01:00-05:00,ABBV,positive
9123.0,AbbVie Receives US FDA Accelerated Approval For VENCLEXTA For Treatment Of Newly-Diagnosed Acute Myeloid Leukemia Patients Ineligible For Intensive Chemotherapy,2018-11-21 14:14:00-05:00,ABBV,positive
9124.0,AbbVie Reports Presented Phase 3 Data Showing Investigational Elagolix Reduces Heavy Menstrual Bleeding in Women with Uterine Fibroids at 2018 AAGL Global Congress,2018-11-14 17:36:00-05:00,ABBV,neutral
9125.0,AbbVie Reports MAVYRET Showed High Virologic Cure Rates In Treatment-Naïve Hepatitis C Patients With Compensated Cirrhosis,2018-11-13 11:31:00-05:00,ABBV,neutral
9126.0,AbbVie Announces HUMIRA Global Patent License With Momenta,2018-11-06 16:48:00-05:00,ABBV,neutral
9127.0,"Argus Maintains Buy on AbbVie, Lowers Price Target to $115",2018-11-06 09:57:00-05:00,ABBV,negative
9128.0,"Lannett Announces Expanded Agreement With Strategic Alliance Partner, HEC Pharm Group, To Distribute Two FDA-Approved Products",2018-11-06 06:54:00-05:00,ABBV,positive
9129.0,"BMO Capital Maintains Underperform on AbbVie, Lowers Price Target to $71",2018-11-05 10:09:00-05:00,ABBV,negative
9130.0,From AbbVie Conference Call: Co. Says Will Continue With A Very Similar Price For Humira In The US Next Year,2018-11-02 09:42:00-04:00,ABBV,neutral
9131.0,From AbbVie Conference Call: Co. Says Continues To Expect 2018 Humira Sales Of Approximately $13.7B+,2018-11-02 09:32:00-04:00,ABBV,neutral
9132.0,From AbbVie Conference Call: Co. Says More Than Half Of Humira Sales In US Driven By Volume Growth,2018-11-02 09:25:00-04:00,ABBV,positive
9133.0,AbbVie Raises Quarterly Dividend From $0.96 To $1.07/Share,2018-11-02 07:49:00-04:00,ABBV,neutral
9134.0,AbbVie Raises FY18 Adj. EPS Guidance From $7.76-$7.86 To $7.90-$7.92 vs $7.88 Est.,2018-11-02 07:49:00-04:00,ABBV,neutral
9135.0,"AbbVie Q3 Adj. EPS $2.14 Beats $2.01 Estimate, Sales $8.24B Beat $8.22B Estimate",2018-11-02 07:48:00-04:00,ABBV,neutral
9136.0,'AbbVie offers a 'huge' discount on Humira to fend off European rivals' -STAT News' Adam Feuerstein Now Tweets Article From Wed. Afternoon,2018-11-01 13:28:00-04:00,ABBV,neutral
9137.0,"Stocks Which Set New 52-Week Low Yesterday, October 31st",2018-11-01 10:37:00-04:00,ABBV,negative
9138.0,AbbVie Offers Results From CLL14 Phase 3 Trial: Met Primary Endpoint Showing 'patients treated with venetoclax plus obinutuzumab had superior progression-free survival compared to patients treated with standard of care obinutuzumab plus chlorambucil',2018-10-31 16:27:00-04:00,ABBV,positive
9139.0,"US Justice Department Says Abbott Laboratories, Abbvie To Pay $25M To Resolve Case Over Tricor Marketing",2018-10-26 14:38:00-04:00,ABBV,positive
9140.0,"Stocks Which Set New 52-Week Low Yesterday, October 23rd",2018-10-24 10:06:00-04:00,ABBV,negative
9141.0,"Stocks Which Set New 52-Week Low Yesterday, October 22nd",2018-10-23 09:54:00-04:00,ABBV,negative
9142.0,"AbbVie Reports Upadacitinib Showed Improvements In Physical Function, Pain, Quality Of Life As Monotherapy In Patients with Rheumatoid Arthritis In Phase 3 Patients-Reported Outcomes Data",2018-10-23 09:07:00-04:00,ABBV,negative
9143.0,AbbVie Reports Upadacitinib Met Primary And All Ranked Secondary Endpoints In Ulcerative Colitis Patients,2018-10-22 18:02:00-04:00,ABBV,neutral
9144.0,"Mylan Launches Hulio, A Biosimilar To AbbVie's Humira, In Markets Across Europe",2018-10-19 12:54:00-04:00,ABBV,neutral
9145.0,"AbbVie Announces Global Resolution Of HUMIRA Patent Disputes With Fresenius Kabi; Agreements Provide Non-Exclusive License To Fresenius Kabi For HUMIRA-Related IP In US Effective Sept. 2023, Fresenius Acknowledges Abbvie's Intellectual Priperty For Humira",2018-10-18 08:52:00-04:00,ABBV,positive
9146.0,AbbVie And Morphic Therapeutic Announce Collaboration Targeting Fibrotic Diseases,2018-10-18 08:00:00-04:00,ABBV,neutral
9147.0,AbbVie Announces Supplemental New Drug Application Accepted For Priority Review By FDA for IMBRUVICA In Combination With Obinutuzumab For Previously Untreated Chronic Lymphocytic Leukemia,2018-10-17 08:01:00-04:00,ABBV,positive
9148.0,"UPDATE: Sandoz Will Pay Royalties To AbbVie For Licensing HUMIRA Patents, Acknowledges Validity Of Licensed Patents",2018-10-11 16:33:00-04:00,ABBV,negative
9149.0,"UPDATE: AbbVie Says License Period With Sandoz Will Begin Sep. 30, 2023 In US, 'will not be accelerated by the entry of companies who have already taken a license'",2018-10-11 16:33:00-04:00,ABBV,neutral
9150.0,UPDATE: AbbVie Will Grant Sandoz Non-Exclusive License To Co.'s IP Related To HUMIRA,2018-10-11 16:32:00-04:00,ABBV,positive
9151.0,AbbVie Reports Global Resolution Of HUMIRA Patent Disputs With Sandoz,2018-10-11 16:32:00-04:00,ABBV,neutral
9152.0,AbbVie To Present New Data For Upadacitinib and HUMIRA® (adalimumab) At 2018 ACR/ARHP Annual Meeting October 19-24,2018-10-08 08:33:00-04:00,ABBV,neutral
9153.0,AbbVie Late Friday Announced Receipt Of Health Canada Approval For ORILISSA For The Treatment Pain Associated With Endometriosis,2018-10-08 07:43:00-04:00,ABBV,negative
9154.0,UPDATE: AbbVie Says Approval Is Based On Murano Phase 3 Clinical Trial Data; Study Showed Significant Improvement In Progression-Free Survival,2018-09-25 16:49:00-04:00,ABBV,positive
9155.0,AbbVie Receives Approval From Health Canada For Combination Of VENCLEXTA With Rituximab As A Treatment For Patients With Chronic Lymphocytic Leukemia,2018-09-25 16:48:00-04:00,ABBV,positive
9156.0,'$abbv being sued today by California for price collusion.   This the least of the problems. Wait until the government starts exploring the rapid and unjustifiable death rate from Humira tgt $60' - Citron Research Tweets,2018-09-18 14:32:00-04:00,ABBV,negative
9157.0,UPDATE: California Dept. Of Insurance Commissioner Dave Jones Suit Against AbbVie Related To Illegal Kickbacks In Promoting Humira,2018-09-18 14:22:00-04:00,ABBV,negative
9158.0,Abbvie Shares Down ~1.3% As California Insurance Regulator Sues Co. Over Alleged Kickbacks,2018-09-18 14:02:00-04:00,ABBV,positive
9159.0,"AbbVie Reports Longer-Term, Patient-Reported Outcomes Data For Upadacitinib Phase 2b Atopic Dermatitis Study: Patients 'showed continuous improvements in skin lesions and pruritus (itch) at week 32'",2018-09-13 09:21:00-04:00,ABBV,positive
9160.0,AbbVie Reports Patient-Reported Outcomes Data From 3 Pivotal Phase 3 Studies Of Risankizumab Showing Improvements In Health-Related Quality Of Life For Patients With Psoriasis,2018-09-13 06:26:00-04:00,ABBV,positive
9161.0,AbbVie Reports FDA Expanded Label For VENCLEXTA In Combo With Rituximab to Include Info About Patients With Previously-Trated Chronic Lymphocytic Leukemia Who Achieved Minimal Residual Disease Negativity In Phase 3 MURANO Trial,2018-09-11 08:18:00-04:00,ABBV,negative
9162.0,"Geron Shares Remain Elevated, Up 28.3% With Some Attributing Upside To Johnson & Johnson Job Posting For a Strategic Pricing Manager For Imbruvica & Imetelstat, Drugs Its Partnered On With AbbVie and Geron, Respectively",2018-08-24 10:42:00-04:00,ABBV,positive
9163.0,UPDATE: AbbVie Says No New Safety Signals Identified,2018-08-22 08:33:00-04:00,ABBV,positive
9164.0,AbbVie Offers Topline Results From Phase 3 Extension Study Evaluating Investigational Elagolix In Women With Uterine Fibroids: Showed Reduction In Heavy Menstrual Bleeding For Up To 12 Months,2018-08-22 08:33:00-04:00,ABBV,neutral
9165.0,Argenx Announces Abbvie Has Exercised Its Exclusive Option to License Argx-115; Argenx Eligible to Receive up to $625M in Milestone Payments,2018-08-22 04:06:00-04:00,ABBV,positive
9166.0,AbbVie Option Alert: Fri $88.5 Puts Sweep (26) near the Ask: 653 @ $0.614 vs 124 OI; Ref=$89.76,2018-07-30 12:04:00-04:00,ABBV,positive
9167.0,AbbVie Option Alert: Fri $92 Puts Sweep (11) near the Ask: 500 @ $3.0 vs 3600 OI; Earnings 7/27 Before Open Ref=$88.989,2018-07-27 10:22:00-04:00,ABBV,positive
9168.0,Abbvie On Conf. Call Says They Expect Intl. Humira Sales To Approach $6.4B This Year,2018-07-27 09:44:00-04:00,ABBV,neutral
9169.0,"AbbVie Q2 EPS $2 Beats $1.97 Estimate, Sales $8.258B Beat $8.21B Estimate",2018-07-27 07:38:00-04:00,ABBV,neutral
9170.0,Neurocrine Biosciences 8-K Highlights FDA Approval Of AbbVie's ORILISSA; Co. To Receive $40M Event-Based Payment Made By AbbVie,2018-07-24 14:36:00-04:00,ABBV,positive
9171.0,AbbVie Reports Received FDA Approval For ORILISSA For Mgmt. Of Moderate To Severe Pain Associated With Endometriosis,2018-07-24 08:30:00-04:00,ABBV,negative
9172.0,AbbVie Option Alert: Sep 21 $85 Puts Sweep (21) near the Ask: 750 @ $3.151 vs 1765 OI; Earnings 7/27 Before Open Ref=$86.985,2018-07-20 11:56:00-04:00,ABBV,positive
9173.0,"Adam Feuerstein, Responding To A Tweet That Citron Will Have More Abbvie Reports Out Soon, Tweets 'This promotional front-running nonsense erodes credibility.' (2/2)",2018-07-20 10:59:00-04:00,ABBV,negative
9174.0,"Adam Feuerstein, Responding To A Tweet That Citron Will Have More Abbvie Reports Out Soon, Tweets 'In lieu of actual reports or information, let's just hype-tweet the threat of reports. If you have information, put it out there.' (1/2)",2018-07-20 10:58:00-04:00,ABBV,negative
9175.0,AbbVie Option Alert: Aug 17 $87.5 Puts at the Ask: 800 @ $2.3 vs 2213 OI; Earnings 7/27 Before Open Ref=$89.725,2018-07-19 11:25:00-04:00,ABBV,positive
9176.0,'Is there something about $ABBV and the Humira patents...that the market doesn't already know about? Or is @CitronResearch just going to huff and puff the stock lower?' - STAT News' Adam F Tweets,2018-07-19 10:52:00-04:00,ABBV,neutral
9177.0,UPDATE: AbbVie Will Make No Payments To Mylan,2018-07-17 08:08:00-04:00,ABBV,negative
9178.0,"UPDATE: Mylan Will Pay AbbVie For Licensing HUMIRA Patents Once Its Biosimilar Product Is Launched, No Terms Disclosed",2018-07-17 08:07:00-04:00,ABBV,negative
9179.0,"UPDATE: Mylan's US License For HUMIRA Will Begin On Jul. 31, 2023 And Will Not Be Accelerated By Amgen, Samsung Bioepis Entry",2018-07-17 08:07:00-04:00,ABBV,neutral
9180.0,"UPDATE: AbbVie To Grant Mylan Non-Exclusive License On Specified Dates To AbbVie's Intellectual Property Related To HUMIRA In US, Various Other Countries, Excluding Europe",2018-07-17 08:06:00-04:00,ABBV,positive
9181.0,AbbVie Reports HUMIRA Patent License With Mylan,2018-07-17 08:06:00-04:00,ABBV,neutral
9182.0,"Berenberg Initiates Coverage On AbbVie with Hold Rating, Announces $105 Price Target",2018-07-12 08:15:00-04:00,ABBV,neutral
9183.0,AbbVie Announces Submission of sNDA to FDA for Venetoclax in Newly Diagnosed Acute Myeloid Leukemia Patients Ineligible for Intensive Chemotherapy,2018-07-12 03:57:00-04:00,ABBV,neutral
9184.0,"AbbVie Says The DBL3001 Study Did Not Show Additional Efficacy When Adding ibrutinib , But Clincially-Meaningful Response Was Observed In A Patient Sub-Population  Warranting Further Analysis",2018-07-11 08:02:00-04:00,ABBV,neutral
9185.0,U.S. Judge Overturns $140M Verdict Against Abbvie In Lawsuit Over Androgel Risks,2018-07-05 13:34:00-04:00,ABBV,negative
9186.0,Argenx Receives $10M Milestone Payment Under Development Agreement With AbbVie,2018-06-28 04:07:00-04:00,ABBV,positive
9187.0,AbbVie and Calico Announce 3-Year Extension of Collaboration To Focus On Aging And Age-Related Diseases,2018-06-26 08:02:00-04:00,ABBV,neutral
9188.0,AbbVie and Scripps' Calibr Announce Collaboration for T-Cell Therapies Aimed at Cancer,2018-06-25 07:03:00-04:00,ABBV,negative
9189.0,AbbVie and Eisai Announce Launch of HUMIRA for Subcutaneous Injection 20 mg Syringe 0.2 mL,2018-06-21 04:10:00-04:00,ABBV,neutral
9190.0,AbbVie Announces New Undetectable Minimal Residual Disease Data from Phase 3 Relapsed/Refractory Chronic Lymphocytic Leukemia MURANO Trial of Venetoclax in Combination with Rituximab at #EHA2018,2018-06-15 04:36:00-04:00,ABBV,neutral
9191.0,AbbVie Presents Additional Outcomes Data from Three Upadacitinib Phase 3 Studies in RA at EULAR 2018,2018-06-13 04:33:00-04:00,ABBV,neutral
9192.0,"Argus Maintains Buy on AbbVie, Lowers Price Target to $130",2018-06-11 08:07:00-04:00,ABBV,negative
9193.0,"AbbVie,d Eisai Announce Launch of HUMIRA Pen, an Auto-Injector Formulation for Fully Human Anti-TNF-alpha Monoclonal Antibody HUMIRA",2018-06-11 03:57:00-04:00,ABBV,neutral
9194.0,"FDA Wins Approval For AbbVie, Genentech's Venclexta For Treatment Of Patients With Chronic Lymphocytic Leukemia Or Small Lymphocytic Lymphoma",2018-06-08 13:42:00-04:00,ABBV,positive
9195.0,Abbvie Announces Upadacitinib Monotherapy Meets All Primary and Ranked Secondary Endpoints Versus Methotrexate in a Phase 3 Study in Rheumatoid Arthritis,2018-06-05 08:31:00-04:00,ABBV,neutral
9196.0,"Donald Trump Tweets: 'We had Repeal & Replace done (and the saving to our country of one trillion dollars) except for one person, but it is getting done anyway'...'less expensive plans will be announced this month. Drug prices coming down & Right to Try!'",2018-06-04 08:22:00-04:00,ABBV,neutral
9197.0,AbbVie AbbPhase 2 IMBRUVICA Plus VENCLEXTA Early Data Show High Rates of Responses in Patients with Previously-Untreated CLL at #ASCO2018,2018-06-03 19:08:00-04:00,ABBV,neutral
9198.0,Abbvie Announces Phase 3 Data For IMBRUVICA Suggests Improved Treatment Outcomes In Waldenstrom's Macroglubulinemia,2018-06-01 16:47:00-04:00,ABBV,positive
9199.0,PiperJaffray Downgrades AbbVie to Neutral,2018-06-01 08:38:00-04:00,ABBV,neutral
9200.0,"AbbVie Announces Prelim. Results Of Modified Dutch Auction Tender; Total of 74,033,457 Shares Common Stock Tendered At/Bleow $103/Share",2018-05-30 16:47:00-04:00,ABBV,positive
9201.0,AbbVie Tenders 75.74M Shars At $105/Share,2018-05-30 08:07:00-04:00,ABBV,positive
9202.0,"Credit Suisse Downgrades AbbVie to Underperform, Lowers Price Target to $89",2018-05-30 06:50:00-04:00,ABBV,positive
9203.0,UPDATE: AbbVie Says IMBRUVICA Plus GAZYVA Full Study Results Could Support IMBRUVICA-Based Chemotherapy-Free Combo Treatment Option For Patients,2018-05-24 09:03:00-04:00,ABBV,positive
9204.0,AbbVie Reports IMBRUVICA Plus GAZYVA Phase 3 iLLUMINATE Trial For First-Line Therapy Of Chronic Lymphocytic Leukemia Patients Met Primary Endpoint,2018-05-24 09:02:00-04:00,ABBV,neutral
9205.0,AbbVie Reports Submission Of Marketing Authorization Application To EMA For Risankizumab For Moderate To Severe Plaque Psoriasis,2018-05-01 08:47:00-04:00,ABBV,negative
9206.0,AbbVie Reports Commencement Of Self-Tender Offer For Up To $7.5B In Common Stock,2018-05-01 08:13:00-04:00,ABBV,neutral
9207.0,"Morgan Stanley Maintains Equal-Weight on AbbVie, Lowers Price Target to $110.00",2018-04-30 09:16:00-04:00,ABBV,negative
9208.0,"Credit Suisse Maintains Neutral on AbbVie, Lowers Price Target to $104.00",2018-04-27 08:51:00-04:00,ABBV,positive
9209.0,"Abbvie To Commence Tender Offer For Up To $7.5B Of Common Stock Through Modified 'Dutch Auction' Tender Offer As Early As May 1, 2018",2018-04-26 07:52:00-04:00,ABBV,neutral
9210.0,AbbVie Raises Guidance From $7.33-$7.43 To $7.66-$7.76,2018-04-26 07:51:00-04:00,ABBV,neutral
9211.0,"AbbVie Q1 EPS $1.87 Beats $1.79 Est., Sales $7.93B Beats $7.6B Est.",2018-04-26 07:51:00-04:00,ABBV,neutral
9212.0,AbbVie Submits BLA Application To FDA for Risankizumab,2018-04-25 09:06:00-04:00,ABBV,neutral
9213.0,"AbbVie Reports Upadacitinib Met Primary, Key Efficacy Endpoints In Phase 2b/3 RA Study In Japanese Patients",2018-04-25 08:30:00-04:00,ABBV,neutral
9214.0,AbbVie's Upadacitnib Met its Primary Endpoints,2018-04-09 08:48:00-04:00,ABBV,neutral
9215.0,"Barclays Maintains Equal-Weight on AbbVie, Lowers Price Target to $102.00",2018-04-05 13:44:00-04:00,ABBV,negative
9216.0,"AbbVie Reports Global Resolution Of HUMIRA Patent Disputes With Samsung Bioepis; Deal Provides Non-Exclusive License To Samsung Bioepis For HUMIRA-Related IP In US, Effective Jun. 30, Other Markets On Diff. Dates",2018-04-05 08:07:00-04:00,ABBV,positive
9217.0,"Biogen, Samsung Bioepis Reach Deal With AbbVie For Commercialization Of IMRALDI In Europe",2018-04-05 08:06:00-04:00,ABBV,neutral
9218.0,"BMO Capital Maintains Underperform on AbbVie, Lowers Price Target to $80.00",2018-03-23 07:47:00-04:00,ABBV,negative
9219.0,Abbvie Shares Down 13.7% After Co. Earlier Backed Away From Pursuing Early Approval Of Rova-T After Disappointing Study Data,2018-03-22 11:59:00-04:00,ABBV,positive
9220.0,AbbVie Shares Not Reacting Dramatically As Hearing Jefferies Out Negative On Outcome For Co.'s TRINITY Trial Could Impact Earnings By 4-5%,2018-03-22 10:14:00-04:00,ABBV,negative
9221.0,"UPDATE: AbbVie Says Ongoing Phase 3 Studies, MERU, TAHOE, To Continue To Investigate Rova-T In 1st-, 2nd-Line SCLC",2018-03-22 08:48:00-04:00,ABBV,neutral
9222.0,UPDATE: AbbVie Says Rova-T Showed Single Agent Responses In Advanced SCLC Patients,2018-03-22 08:47:00-04:00,ABBV,positive
9223.0,AbbVie Offers Results From Phase 2 Study Of Rova-T In 3rd-Line Treatment Of Patients With DLL3-Expressing Relapsed/Refractory SCLC: Will Not Seek Accelerated Approval,2018-03-22 08:47:00-04:00,ABBV,negative
9224.0,"AbbVie, Int'l. Myeloma Foundation Report Partnership To Study Role Of Genetic Mutation In Outcomes Of Patients With Multiple Myeloma",2018-03-21 09:01:00-04:00,ABBV,neutral
9225.0,AbbVie Announces its  Phase 3 Study of Elagolix Met it Primary Endpoint and All Secondary Endpoints,2018-03-13 08:04:00-04:00,ABBV,neutral
9226.0,Biogen and AbbVie Announce the Voluntary Worldwide Withdrawal of Marketing Authorizations for ZINBRYTA for Relapsing Multiple Sclerosis,2018-03-02 06:26:00-05:00,ABBV,neutral
9227.0,AbbVie Says the First Two Phase 3 Studies Evaluating Investigational Elagolix in Women with Uterine Fibroids Met Primary Endpoints,2018-02-21 08:05:00-05:00,ABBV,neutral
9228.0,"Voyager Therapeutics to Collaborate with Abbvie on Treatments for Alzheimer's Disease, Voyager to Revive a $69M Upfront Payment",2018-02-20 07:02:00-05:00,ABBV,positive
9229.0,"UPDATE: AbbVie New Phase 2 Data On Upadacitinib 'overall safety profile of upadacitinib was consistent with that observed in other upadacitinib studies, with no new safety signals detected'",2018-02-16 11:21:00-05:00,ABBV,positive
9230.0,"AbbVie Reports New Phase 2 Data For Upadacitinib For Clinical, Endoscopic Outcomes In Crohn's Disease: 'showed that many upadacitinib-treated patients who achieved clinical response'",2018-02-16 11:21:00-05:00,ABBV,neutral
9231.0,"Abbvie Opens, Now Up 1.96% At $115.32/Share",2018-02-15 13:01:00-05:00,ABBV,neutral
9232.0,Hearing Abbvie Indicated $114.50-$117.50,2018-02-15 12:59:00-05:00,ABBV,neutral
9233.0,AbbVie Increases Qtr. Dividend From $0.71 To $0.96/Share,2018-02-15 12:49:00-05:00,ABBV,neutral
9234.0,AbbVie Reports New $10B Buyback Plan,2018-02-15 12:49:00-05:00,ABBV,neutral
9235.0,BZ NOTE On Trading Halt In AbbVie: Co. Issued Press Release On Mon. Highlighting Will Showcase Investigational Data At AAD Meeting On Sat.,2018-02-15 12:46:00-05:00,ABBV,positive
9236.0,AbbVie Shares Halted News Pending,2018-02-15 12:40:00-05:00,ABBV,positive
9237.0,"Gilead Shares Unaffected, AbbVie Shares Move Lower Amid Capitol Forum Report 'Rep. Khanna and Other Democrats Urge HHS to Take Patents, Pave Way for Cheaper HCV Generics'",2018-02-15 09:59:00-05:00,ABBV,positive
9238.0,"Argus Maintains Buy on AbbVie, Raises Price Target to $145.00",2018-02-02 09:56:00-05:00,ABBV,neutral
9239.0,"Morgan Stanley Maintains Equal-Weight on AbbVie, Raises Price Target to $131.00",2018-01-30 09:27:00-05:00,ABBV,neutral
9240.0,BMO Capital Downgrades AbbVie to Underperform,2018-01-30 09:07:00-05:00,ABBV,neutral
9241.0,Credit Suisse Raises AbbVie Price Target From $98 To $135 On Stronger Than Expected Humana Growth And A Significantly Lowered Tax Rate From The U.S. Tax Cuts And Jobs Act,2018-01-29 09:06:00-05:00,ABBV,positive
9242.0,Leerink Swann Downgrades AbbVie to Market Perform,2018-01-29 08:54:00-05:00,ABBV,neutral
9243.0,AbbVie Says Plans To Make Investments Of ~$2.5B Over Next 5 Years In US Capital Projects,2018-01-26 07:52:00-05:00,ABBV,neutral
9244.0,AbbVie Raises FY18 Adj. EPS Outlook From $6.37-$6.57 To $7.33-$7.43 vs $6.59 Est.,2018-01-26 07:52:00-05:00,ABBV,neutral
9245.0,"AbbVie Reports Q4 Adj. EPS $1.48 vs $1.44 Est., Sales $7.739B vs $7.53B Est.",2018-01-26 07:51:00-05:00,ABBV,neutral
9246.0,Abbvie CEO Says upadacitinb Immunocology Drug Can Reach $6.5B In Sales By 2025 With 6 Indications,2018-01-10 11:47:00-05:00,ABBV,neutral
9247.0,Abbvie CEO Plans To Advance Neuroscience Pipeline To Contribute To Sales Growth In The Coming Decade,2018-01-10 11:43:00-05:00,ABBV,positive
9248.0,AbbVie Earlier Announced FDA Granted Breakthrough Therapy Designation To ABT-494,2018-01-08 12:17:00-05:00,ABBV,positive
9249.0,The $150M Verdict Against Abbvie for Androgel is Thrown Out,2017-12-22 15:16:00-05:00,ABBV,positive
9250.0,"AbbVie Reports Upadacitinib Showed Positive Results As Monotherapy In Phase 3 RA Study, Met All Primary, Key Secondary Endpoints",2017-12-20 08:01:00-05:00,ABBV,positive
9251.0,"STAT News' Adam Feuerstein Responds To Tweet Highlighting '$PFE $AGN rumor - no source': 'The other day I heard $PFE for $BMY,' 'Also $ABBV for $BMY'",2017-12-14 10:05:00-05:00,ABBV,negative
9252.0,AbbVie Reports Phase 3 Study Of VENCLEXTA/VENCLYXTO Combo with Rituxan Met Primary Endpoint,2017-12-12 07:30:00-05:00,ABBV,neutral
9253.0,"Abbvie Reports IMVRUVICA Clinical Results Suggest Drug Inhibits B Cells and Follicular Helper T-Cells That Are Thought To Play Crucial ROle In Treating cGVHD, While Preserving Immune Memory and Th1 T Cells",2017-12-11 10:02:00-05:00,ABBV,positive
9254.0,AbbVie's INBRUVICA Plus Rituzimax Phase 3 iNNOVATE Trial in Rare Waldenstroem's Macroglobulinemia Met its Primary Endpoint,2017-12-05 08:04:00-05:00,ABBV,positive
9255.0,AbbVie Reports Fourth Pivotal Phase 3 Psoriasis Study For Risankizumab Met All Primary Endpoints,2017-12-04 08:25:00-05:00,ABBV,neutral
9256.0,Enanta Says AbbVie's MAVIRET Is Now Available In Japan For Treatment Of GT1-6,2017-11-30 07:30:00-05:00,ABBV,neutral
9257.0,"BMO Capital Maintains Market Perform on AbbVie, Raises Price Target to $84.00",2017-11-16 09:36:00-05:00,ABBV,neutral
9258.0,AbbVie Announces 'Positive' Phase 3 Extension Study Data For Elagolix,2017-11-01 12:02:00-04:00,ABBV,neutral
9259.0,"Adam Feuerstein Tweets: FDA approves $AZN acalabrutinib for patients w/ mantle cell lymphoma. Brand name: Calquence. 

Recall, this is the ""Imbruvica killer."" $ABBV",2017-10-31 11:49:00-04:00,ABBV,positive
9260.0,Abbvie CEO on Conf. Call Says It'd Attempt To Get A Prelim. Injuction To Block Any Launches That Violate Humira IP,2017-10-27 10:27:00-04:00,ABBV,negative
9261.0,"AbbVie Sees FY17 Adj. EPS $5.33-$5.55 vs $5.53 Est., FY18 Adj. EPS $6.37-$6.57 vs $6.56 Est.",2017-10-27 07:51:00-04:00,ABBV,neutral
9262.0,"AbbVie Reports Q3 Adj. EPS $1.41 vs $1.38 Est., Sales $6.995B vs $7B Est.",2017-10-27 07:50:00-04:00,ABBV,neutral
9263.0,AbbVie Raises Qtr. Dividend From $0.64 To $0.71/Share,2017-10-27 07:30:00-04:00,ABBV,neutral
9264.0,AbbVie Reports FDA Priority Review For Elagolix For Mgmt. Of Endometriosis With Associated Pain,2017-10-27 07:05:00-04:00,ABBV,negative
9265.0,"AbbVie Reports Risankizumab Met All Co-Primary, Ranked Secondary Endpoints In 3 Pivotal Phase 3 Psoriasis Studies",2017-10-26 08:12:00-04:00,ABBV,neutral
9266.0,"Alector and AbbVie Report Partnership to Advance a Novel Class of Immune Therapies for Patients with Alzheimer's Disease, Will Co-Fund Development and Commercialization And Will Share Global Profits Equally",2017-10-24 07:09:00-04:00,ABBV,positive
9267.0,"AbbVie Shares Indicated Up 0.2% After Hours, Could Be Related To Celgene News Co. Discontinuing Crohn's Disease Drug Trial",2017-10-19 17:02:00-04:00,ABBV,positive
9268.0,AbbVie and Harpoon Therapeutics Report Immuno-Oncology Research Collaboration,2017-10-18 08:32:00-04:00,ABBV,neutral
9269.0,Cowen & Co. Upgrades AbbVie to Outperform,2017-10-11 06:35:00-04:00,ABBV,neutral
9270.0,AbbVie Reports Global Collaboration On Viral Immunotherapies In Oncology With Turnstone Biologics,2017-10-10 08:04:00-04:00,ABBV,neutral
9271.0,Leerink Swann Upgrades AbbVie to Outperform,2017-10-02 07:35:00-04:00,ABBV,neutral
9272.0,"AbbVie Says 'Agreements Provide Non-Exclusive License to Amgen for HUMIRA-Related Intellectual Property in the U.S. Effective Jan. 31, 2023, And in Other Markets on Different Dates'",2017-09-28 08:01:00-04:00,ABBV,positive
9273.0,AbbVie Reports Resolution Of HUMIRA Patent Disputes With Amgen,2017-09-28 08:00:00-04:00,ABBV,negative
9274.0,"AbbVie Shares Dip ~$1 To Fresh Session Lows, Stock Down 2.2% For Session",2017-09-27 11:06:00-04:00,ABBV,positive
9275.0,Enanta Pharma Says AbbVie's MAVIRET Received Approval in Japan for Treatment of Chronic Hepatitis C,2017-09-27 06:30:00-04:00,ABBV,positive
9276.0,UBS Downgrades AbbVie to Neutral,2017-09-25 06:47:00-04:00,ABBV,neutral
9277.0,AbbVie and Bristol-Myers Announce Clinical Research Collaboration to Evaluate a Therapeutic Regimen in Advanced Solid Tumors,2017-09-22 07:00:00-04:00,ABBV,positive
9278.0,Abbvie Trial Met Primary Endpoint In Phase 3 Trial For VENCLEXTA,2017-09-18 11:32:00-04:00,ABBV,neutral
9279.0,"AbbVie Reports ABT-494 Met All Primary, Ranked Secondary Endpoints In Second Phase 3 Trial For RA",2017-09-11 08:04:00-04:00,ABBV,neutral
9280.0,"AbbVie Shares Break To Session Highs After Clearing $79, $80, $81, $82 Technical Levels; Stock Up ~6% For Session",2017-09-07 12:12:00-04:00,ABBV,positive
9281.0,Coherus Shares Down ~$0.45 Over Last Few Mins. As Traders Circulating Word AbbVie Prevailed Against Co. In IPR Patent Trial '619,2017-09-07 11:18:00-04:00,ABBV,positive
9282.0,AbbVie Reports Submission Of NDA For Investigational Oral Treatment Elagolix For Mgmt. Of Endometriosis With Associated Pain,2017-09-06 08:01:00-04:00,ABBV,negative
9283.0,"Evercore ISI Group Initiates Coverage On AbbVie with Outperform Rating, Announces $95.00 Price Target",2017-08-17 06:31:00-04:00,ABBV,neutral
9284.0,13F From Farallon Capital Shows New 835K Share Stake In AbbVie,2017-08-14 13:55:00-04:00,ABBV,positive
9285.0,"Adam Feuerstein Tweets: $GILD competition. 

And $ENTA gets a piece of Mavyret.",2017-08-03 15:10:00-04:00,ABBV,neutral
9286.0,FDA Grants Approval For Abbvie's Mavyret For Hepatitis C,2017-08-03 15:07:00-04:00,ABBV,positive
9287.0,AbbVie Reports U.S. FDA Approves IMBRUVICA,2017-08-02 13:08:00-04:00,ABBV,positive
9288.0,Enanta To Receive $25M Milestone Payment From AbbVie Following EU Marketing Authorization For MAVIRET,2017-07-28 11:07:00-04:00,ABBV,neutral
9289.0,European Commission Grants AbbVie's MAVIRET Marketing Authorization,2017-07-28 10:59:00-04:00,ABBV,positive
9290.0,AbbVie Reaffirms FY17 Adj. EPS $5.44-$5.54 vs $5.53 Est.,2017-07-28 07:44:00-04:00,ABBV,neutral
9291.0,"AbbVie Reports Q2 Adj. EPS $1.42 vs $1.40 Est., Sales $6.944B vs $6.93B Est.",2017-07-28 07:43:00-04:00,ABBV,neutral
9292.0,AbbVie Receives CHMP Positive Opinion for HUMIRA,2017-07-21 09:37:00-04:00,ABBV,positive
9293.0,"Shares of Eli Lilly, AstraZeneca, Merck, Gilead, Abbvie, Other Large Cap Biotech Spiking Higher",2017-07-13 14:43:00-04:00,ABBV,positive
9294.0,CytomX Therapeutics Reports Achieved Development Milestone In Strategic Oncology Collab With AbbVie For CD71-Targeting Probody Drug Conjugate,2017-06-29 08:04:00-04:00,ABBV,neutral
9295.0,AbbVie Receives CHMP Positive Opinion for MAVIRET,2017-06-23 08:50:00-04:00,ABBV,positive
9296.0,EMA Recommends Approval For AbbVie's Hep C Combo,2017-06-23 07:31:00-04:00,ABBV,positive
9297.0,"AbbVie, Principia Report Partnership on Oral Immunoproteasome Inhibitors, Terms Not Disclosed",2017-06-13 08:30:00-04:00,ABBV,negative
9298.0,"Watch Regeneron, AbbVie and OncoSec as FDA Shows Orphan Status Granted",2017-06-08 07:52:00-04:00,ABBV,positive
9299.0,Synlogic Issues Release Highlighting Co. Met First Discovery Milestone in AbbVie Partnership,2017-06-07 08:17:00-04:00,ABBV,neutral
9300.0,"AbbVie Reports ABT-494 Met All Primary, Ranked Secondary Endpoints in Phase 3 Study in RA",2017-06-07 08:00:00-04:00,ABBV,neutral
9301.0,"UBS Global Health Care Conference Begins Today; Presenters Include: AbbVie, Aetna, Universal Health, Mylan, Community Health, Tenet Healthcare, & Bristol-Myers Squibb",2017-05-22 08:57:00-04:00,ABBV,positive
9302.0,"AbbVie Issues Press Release Highlighting Presentation of Primary, Secondary Efficacy, Safety Data from Pivotal Phase 3 Trial of Elagolix at World Congress on Endometriosis",2017-05-17 12:01:00-04:00,ABBV,positive
9303.0,"U.S. Health Officials Say New Cases Of Hep. C Rose ~300% From 2010 to 2015, Fueled By Spike In Heroin and Other Injection Drugs",2017-05-11 15:13:00-04:00,ABBV,negative
9304.0,AbbVie Reports Positive Phase 2 Study Results for Upadacitinib,2017-05-09 11:01:00-04:00,ABBV,positive
9305.0,"Companies Holding Shareholder Meetings Today Include: AbbVie, Marriott International, MeetMe, TransCanada, & Tribune Media Company",2017-05-05 08:24:00-04:00,ABBV,neutral
9306.0,"Deutsche Bank Healthcare Conference Begins Today; Presenters Include Synergy Pharma, Exelixis, AbbVie, Collegium Pharma, Zimmer Biomet, Luminex, CRISPR Therapeutics, & Edwards Lifesciences",2017-05-03 08:22:00-04:00,ABBV,neutral
9307.0,"Abbvie CEO Says HCV Patient Volumes Still Trending Down Although At Slower Pace, He Thinks They Are Reaching Some Point Of Stability Going Forward",2017-04-27 10:00:00-04:00,ABBV,positive
9308.0,AbbVie Affirms FY17 Adj. EPS $5.44-$5.54 vs $5.50 ESt.,2017-04-27 07:48:00-04:00,ABBV,neutral
9309.0,"AbbVie Reports Q1 Adj. EPS $1.28 vs $1.26 Est., Sales $6.538B vs $6.48B Est.",2017-04-27 07:47:00-04:00,ABBV,neutral
9310.0,"Aquinnah Pharma Reports Received $10M Investment from Pfizer, AbbVie for Research Breakthrough Approach to Neurodegenerative Disease",2017-04-25 08:08:00-04:00,ABBV,neutral
9311.0,Enanta Pharma Reports 8 Weeks of AbbVie's G/P Achieved High SVR Rates in Challenging-to-Treat Genotype 3 Chronic HCV Patients,2017-04-21 06:20:00-04:00,ABBV,neutral
9312.0,"AbbVie Says 'new data demonstrated high SVR(12) rates across compensated cirrhotic patients with genotype 1, 2, 4, 5 or 6 chronic HCV infection with 12 weeks of treatment'",2017-04-20 07:35:00-04:00,ABBV,neutral
9313.0,AbbVie Reports Regimen of Glecaprevir/Pibrentasvir Achieved 99% SVR Rate in Chronic Hep C Patients with Compensated Cirrhosis,2017-04-20 07:34:00-04:00,ABBV,neutral
9314.0,Abbvie Shares Down 2.8% After 2 Trials of Veliparib did Not Meet Endpoints,2017-04-19 17:53:00-04:00,ABBV,positive
9315.0,AbbVie Reports Phase 2b Data Showing Elagolix Significantly Reduced Heavy Menstrual Bleeding in Women with Uterine Fibroids,2017-04-07 08:00:00-04:00,ABBV,neutral
9316.0,AbbVie Reports IMRUVICA sNDA for Previously-Treated cGVHD Accepted for FDA Review,2017-04-04 07:02:00-04:00,ABBV,positive
9317.0,AbbVie Reports FDA Approval of Addition to Moderate to Severe Fingernail Psoriasis Data to Co.'s HUMIRA Prescribing Information,2017-03-30 07:02:00-04:00,ABBV,positive
9318.0,AbbVie and M2Gen Report New Partnership For ORIEN Avatar Research Program,2017-03-28 08:02:00-04:00,ABBV,neutral
9319.0,AbbVie Shares Up ~$0.20 Over Last Min as Hearing SocGen Upgraded Stock to Hold,2017-03-22 13:40:00-04:00,ABBV,positive
9320.0,AbbVie Reports Granted Priority Review in Japan for Investigational Regimen of G/P for Treatment of All Major Genotypes of Chronic Hep C,2017-03-14 08:04:00-04:00,ABBV,positive
9321.0,"Goldman Sachs Adds AbbVie to Conviction Buy List, Raises Price Target from $74 to $80.00",2017-03-10 06:14:00-05:00,ABBV,neutral
9322.0,AbbVie Adds $5B to Buyback Plan,2017-02-17 08:00:00-05:00,ABBV,neutral
9323.0,AbbVie Reports FDA Granted Priority Review for Glecaprevir/Pibrentasvir for Treatment of Chronic Hep C in All GT1-6,2017-02-02 08:01:00-05:00,ABBV,positive
9324.0,Q4 2016 Real-Time Call Brief,2017-01-27 11:10:00-05:00,ABBV,neutral
9325.0,AbbVie On Conf. Call Says It Expects Global Viekira Sales Of $1B In FY17,2017-01-27 10:01:00-05:00,ABBV,neutral
9326.0,AbbVie Says 2016 U.S. Sales OF Humira Grew More Than 24% With Mid-Teens Prescription Growth And Contribution From Price In High Single-Digits,2017-01-27 09:56:00-05:00,ABBV,positive
9327.0,AbbVie Sees FY17 Adj. EPS $5.44-$5.54 vs $5.47 Est.,2017-01-27 07:49:00-05:00,ABBV,neutral
9328.0,AbbVie Sees FY17 EPS $5.44-$5.54 vs. Est. $5.47,2017-01-27 07:49:00-05:00,ABBV,neutral
9329.0,"Abbvie Reports Q4 EPS $1.20 vs. Est. $1.19, Rev. $6.796B vs. Est. $6.92B",2017-01-27 07:48:00-05:00,ABBV,neutral
9330.0,AbbVie Begins Phase 2 Clinical Trial Programs for ABBV-8E12,2017-01-25 08:04:00-05:00,ABBV,neutral
9331.0,U.S. FDA Approves IMBRUVICA as First Treatment Specifically Indicated for Relapsed/Refractory Marginal Zone Lymphoma,2017-01-19 07:01:00-05:00,ABBV,positive
9332.0,"Presenting At JPMorgan Healthcare Conf., Abbvie Says They See At Least 7 Drugs In Clinical Trials From Stemcentrx In 2017",2017-01-11 11:25:00-05:00,ABBV,neutral
9333.0,"AbbVie Presenting At JPMorgan Healthcare Conf., CEO Sees Annual Humira Exceeding Sales Of $18B By 2020",2017-01-11 11:12:00-05:00,ABBV,neutral
9334.0,Abbvie Sees FY17 Adj. EPS Growth Of 13-15%,2017-01-11 11:06:00-05:00,ABBV,positive
9335.0,AbbVie and Pure PMC Partner for Oncology Research,2017-01-09 09:03:00-05:00,ABBV,neutral
9336.0,Abbvie Also Mentioned Positively On CNBC By Najarians,2017-01-04 12:46:00-05:00,ABBV,positive
9337.0,Citigroup Downgrades AbbVie to Neutral,2016-11-28 09:41:00-05:00,ABBV,neutral
9338.0,Credit Suisse Downgrades AbbVie Inc. Common Stock to Neutral,2016-10-31 05:34:00-04:00,ABBV,positive
9339.0,Leerink Swann Initiates Coverage On AbbVie Inc. Common Stock at Market Perform,2016-10-18 06:23:00-04:00,ABBV,neutral
9340.0,JP Morgan Downgrades AbbVie to Neutral,2016-09-08 04:51:00-04:00,ABBV,positive
9341.0,"Raymond James Initiates Coverage on AbbVie at Outperform, Announces $82.00 PT",2016-09-02 06:15:00-04:00,ABBV,neutral
9342.0,BMO Capital Downgrades AbbVie to Market Perform,2016-06-10 06:25:00-04:00,ABBV,neutral
9343.0,"Morgan Stanley Downgrades AbbVie to Equal-weight, Lowers PT to $65.00",2016-06-08 04:18:00-04:00,ABBV,negative
9344.0,Cowen & Company Downgrades AbbVie to Market Perform,2016-06-06 07:34:00-04:00,ABBV,neutral
9345.0,Societe Generale Initiates Coverage on AbbVie at Sell,2016-04-06 11:47:00-04:00,ABBV,neutral
9346.0,"Deutsche Bank Initiates Coverage on AbbVie at Hold, Announces $63.00 PT",2016-03-15 03:54:00-04:00,ABBV,neutral
9347.0,"Citigroup Upgrades AbbVie to Buy, Raises PT to $65.00",2016-02-23 04:23:00-05:00,ABBV,neutral
9348.0,William Blair Initiates Coverage on AbbVie at Outperform,2016-02-05 06:33:00-05:00,ABBV,neutral
9349.0,Abbvie Announces Venetoclax Receives 3rd Breakthrough Therapy Designation from the FDA,2016-01-28 04:29:00-05:00,ABBV,neutral
9350.0,"Atlantic Equities Initiates Coverage on AbbVie at Neutral, Announces $59.00 PT",2015-12-18 08:54:00-05:00,ABBV,neutral
9351.0,AbbVie Announces NEJM Online Publication of Venetoclax Phase 1 Data in Relapsed/Refractory Chronic Lymphocytic Leukemia,2015-12-06 19:15:00-05:00,ABBV,neutral
9352.0,AbbVie Announces Ibrutinib Combination Data Show Promise in Patients with Relapsed/Refractory Multiple Myeloma,2015-12-06 18:58:00-05:00,ABBV,positive
9353.0,"Barclays Downgrades AbbVie to Equal-weight, Lowers PT to $72.00",2015-12-01 04:59:00-05:00,ABBV,negative
9354.0,"Morgan Stanley Upgrades AbbVie to Overweight, Announces $73.00 PT",2015-11-02 09:47:00-05:00,ABBV,negative
9355.0,"Correction: Citigroup Upgrades AbbVie to Neutral, Raises PT to $60.00",2015-09-28 05:04:00-04:00,ABBV,neutral
9356.0,AbbVie's VIEKIRAX Approved in Japan for the Treatment of Genotype 1 Chronic Hepatitis C,2015-09-28 04:04:00-04:00,ABBV,positive
9357.0,"Deutsche Bank Maintains Buy on AbbVie, Raises PT to $85.00",2015-07-29 06:18:00-04:00,ABBV,neutral
9358.0,"SunTrust Robinson Humphrey Initiates Coverage on AbbVie at Buy, Announces $85.00 PT",2015-07-22 07:14:00-04:00,ABBV,neutral
9359.0,AbbVie Reports IMBRUIVCA Now Approved to Treat Waldenstrom's Macroglobulinemia in Europe,2015-07-10 07:11:00-04:00,ABBV,positive
9360.0,Piper Jaffray Initiates Coverage on AbbVie at Overweight,2015-06-16 16:37:00-04:00,ABBV,negative
9361.0,"AbbVie, Galapagos Present Cystic Fibrosis Corrector and Potentiator Screening Approach at ECFS Conference",2015-06-15 03:40:00-04:00,ABBV,neutral
9362.0,Phase 1b Study of Investigational Treatment Venetoclax with Rituximab Shows Clinical Response in Patients with Relapsed/Refractory CLL,2015-06-12 04:20:00-04:00,ABBV,neutral
9363.0,"Jefferies Maintains Buy on AbbVie, Raises PT to $90.00",2015-06-08 07:28:00-04:00,ABBV,neutral
9364.0,"Jefferies Maintains Buy on AbbVie, Lowers PT to $90.00",2015-06-08 07:27:00-04:00,ABBV,negative
9365.0,Pharmacyclics AnnouncesIMBRUVICA Phase Ib/II Data Show Promise in Patients with Chronic Graft-Versus-Host-Disease at ASCO,2015-05-31 09:49:00-04:00,ABBV,positive
9366.0,Analysis of Phase III RESONATE Data Shows Adherence to the Recommended 420mg Dose of IMBRUVICA® (ibrutinib) Results in Improved Efficacy Benefits in Patients with Chronic Lymphocytic Leukemia,2015-05-31 09:46:00-04:00,ABBV,positive
9367.0,AbbVie Presents Positive Results from Phase 1 Studies of Venetoclax in Patients with Multiple Myeloma at ASCO,2015-05-31 09:32:00-04:00,ABBV,positive
9368.0,Phase III HELIOS Study Results Show IMBRUVICA Combination Therapy Significantly Increased Progression-Free Survival in Previously-Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma Patients,2015-05-30 09:25:00-04:00,ABBV,positive
9369.0,"Morgan Stanley Assumes AbbVie at Equal-weight, Announces $72.00 PT",2015-05-28 03:52:00-04:00,ABBV,neutral
9370.0,"JP Morgan Reinstates Outperform on AbbVie, Announces $75.00 PT",2015-05-27 07:18:00-04:00,ABBV,positive
9371.0,"AbbVie Announces Primary, Secondary Endpoints Met for Investigational Hep C Treatment in Japanese Patients Without Cirrhosis",2015-05-26 20:02:00-04:00,ABBV,neutral
9372.0,"Enanta Announces  95% SVR12 Results from AbbVie GIFT-1 Study in Non-cirrhotic, Japanese Patients with Genotype 1b Hep C Virus1",2015-05-26 20:01:00-04:00,ABBV,neutral
9373.0,AbbVie Presents Preliminary Phase 3b Data with VIEKIRAX + EXVIERA in Chronic Hep C Patients with Renal Impairment at ILC 2015,2015-04-25 11:55:00-04:00,ABBV,neutral
9374.0,"FDA Accepts NDA, Grants Priority Review to AbbVie for OBV/PTV/r With RBV",2015-04-24 04:28:00-04:00,ABBV,positive
9375.0,Enanta Pharmaceuticals Announces AbbVie's Investigational Treatment Regimen for Genotype 1 Chronic Hepatitis C Granted Priority Review in Japan,2015-04-15 21:27:00-04:00,ABBV,positive
9376.0,"BMO Capital Upgrades AbbVie to Outperform, Raises PT to $68.00",2015-04-13 06:05:00-04:00,ABBV,neutral
9377.0,"Biogen, AbbVie Announce EMA Validates Marketing Authorisation Application for ZINBRYTA for Treatment of MS",2015-03-27 07:02:00-04:00,ABBV,positive
9378.0,"AbbVie to Acquire Pharmacyclics for $261.25/Share in Cash, Stock",2015-03-05 04:36:00-05:00,ABBV,neutral
9379.0,"AbbVie Submits NDA in Japan for its Investigational, All-Oral, Treatment for Chronic Hepatitis C",2015-02-12 05:47:00-05:00,ABBV,neutral
9380.0,"Citigroup Initiates Coverage on AbbVie at Sell, Announces $48.00 PT",2015-02-09 06:24:00-05:00,ABBV,neutral
9381.0,EC Grants Marketing Authorizations for AbbVie's VIEKIRAX + EXVIERA for Treatment of Chronic Hepatitis C,2015-01-16 04:39:00-05:00,ABBV,positive
9382.0,UPDATE: AbbVie Sees FY2015 EPS $4.25-4.45 vs $4.42 Est,2015-01-08 16:09:00-05:00,ABBV,neutral
9383.0,Enanta Announces  FDA Approval for AbbVie's VIEKIRA PAK,2014-12-22 05:10:00-05:00,ABBV,positive
9384.0,"Galapagos initiates First Phase 1 Study With GLPG1837, to Receive $10M Milestone Payment from AbbVie",2014-12-19 05:11:00-05:00,ABBV,neutral
9385.0,AbbVie Presents Results from Phase 2 Study of Venetoclax in Acute Myelogenous Leukemia at ASH Annual Meeting,2014-12-07 21:06:00-05:00,ABBV,neutral
9386.0,"Jefferies Maintains Buy on AbbVie, Raises PT to $80.00",2014-12-04 07:58:00-05:00,ABBV,neutral
9387.0,"Deutsche Bank Initiates Coverage on AbbVie at Buy, Announces $80.00 PT",2014-11-14 06:05:00-05:00,ABBV,neutral
9388.0,AbbVie Raises FY2014 EPS Guidance from $3.06-3.16 to $3.25-3.27 vs $3.16 Est,2014-10-31 07:50:00-04:00,ABBV,neutral
9389.0,AbbVie Reports Q3 EPS of $0.89 vs $0.77 Est; Revenue of $5.02B vs $4.82B Est,2014-10-31 07:49:00-04:00,ABBV,neutral
9390.0,"ISI Group Initiates Coverage on AbbVie at Buy, Announces $58.00 PT",2014-10-17 06:47:00-04:00,ABBV,neutral
9391.0,AbbVie Board Recommends Shareholders Vote Against Shire Transaction ,2014-10-16 05:02:00-04:00,ABBV,positive
9392.0,"Guggenheim Securities Initiates Coverage on AbbVie at Buy, Announces $70.00 PT",2014-10-02 06:10:00-04:00,ABBV,positive
9393.0,AbbVie Announces Phase 3 Trial Evaluating Efficacy of HUMIRA in Patients with Hidradenitis Suppurativa Met Primary Endpoint,2014-09-11 05:30:00-04:00,ABBV,neutral
9394.0,"AbbVie, Calico Announce  Collaboration To Accelerate The Discovery, Development And Commercialization Of New Therapies ",2014-09-03 13:01:00-04:00,ABBV,neutral
9395.0,"Infinity, AbbVie Enter Global Strategic Collaboration to Develop and Commercialize Duvelisib In Oncology ",2014-09-03 06:46:00-04:00,ABBV,neutral
9396.0,"UBS Upgrades AbbVie to Buy, Raises PT to $67.00",2014-07-28 08:51:00-04:00,ABBV,neutral
9397.0,AbbVie Sees Q3 EPS $0.77-0.79 vs $0.77 Est,2014-07-25 07:47:00-04:00,ABBV,neutral
9398.0,AbbVie Reports Q2 EPS of $0.82 vs $0.76 Est; Revenue of $4.93B vs $4.70B Est; Reaffirms Outlook,2014-07-25 07:47:00-04:00,ABBV,neutral
9399.0,"Jefferies Maintains Buy on AbbVie, Raises PT to $85.00",2014-07-18 13:57:00-04:00,ABBV,neutral
9400.0,"Barclays Upgrades AbbVie to Overweight, Raises PT to $69.00",2014-07-02 06:30:00-04:00,ABBV,negative
9401.0,AbbVie Sees FY2014 EPS $3.06-3.16 vs $3.14 Est,2014-06-23 07:47:00-04:00,ABBV,neutral
9402.0,Shire Rejects AbbVie Proposal ,2014-06-20 05:33:00-04:00,ABBV,negative
9403.0,AbbVie  Findings Show Positive Association Between Adherence and Anti-TNF Therapy Compared to Conventional Therapy,2014-06-11 05:30:00-04:00,ABBV,positive
9404.0,AbbVie Presents Interim Results from Studies of Investigational Oncology Compound ABT-199/GDC-0199 at ASCO,2014-05-31 08:03:00-04:00,ABBV,neutral
9405.0,"Morgan Stanley Upgrades AbbVie to Overweight, Raises PT to $60.00",2014-05-07 06:56:00-04:00,ABBV,negative
9406.0,AbbVie Reports Q1 EPS of $0.71 vs $0.68 Est; Revenue of $4.56B vs $4.33B Est,2014-04-25 07:54:00-04:00,ABBV,neutral
9407.0,"Bank of America Maintains Buy on AbbVie, Lowers PO to $55.00",2014-04-24 06:50:00-04:00,ABBV,negative
9408.0,AbbVie to Present Detailed Phase III Results from SAPPHIRE-I and SAPPHIRE-II Studies in Chronic Hepatitis C Patients at ILC 2014,2014-04-11 05:35:00-04:00,ABBV,neutral
9409.0,AbbVie to Present Detailed Results from Phase III Studies in Patients with Chronic Hepatitis C at ILC,2014-03-24 05:36:00-04:00,ABBV,neutral
9410.0,"Bank of America Maintains Buy on AbbVie, Raises PO to $58.00",2014-02-21 06:52:00-05:00,ABBV,negative
9411.0,AbbVie Invests $320M in Singapore ,2014-02-05 21:53:00-05:00,ABBV,neutral
9412.0,AbbVie Sees FY2013 EPS $3.00-3.10 vs $3.13 Est,2014-01-31 07:47:00-05:00,ABBV,neutral
9413.0,"AbbVie Reports Q4 EPS of $0.82, Inline; Revenue of $5.11B vs $5.10B Est",2014-01-31 07:47:00-05:00,ABBV,neutral
9414.0,"Morgan Stanley Maintains Equal-weight on AbbVie, Lowers PT to $47.00",2014-01-27 06:42:00-05:00,ABBV,negative
9415.0,AbbVie Initiates Pivotal Phase 3 Study of Veliparib for Patients with Early-Stage Triple-Negative Breast Cancer ,2014-01-15 08:04:00-05:00,ABBV,negative
9416.0,"Bank of America Maintains Buy on AbbVie, Raises PO to $56.00",2013-12-31 06:54:00-05:00,ABBV,negative
9417.0,"Morgan Stanley Downgrades AbbVie to Equal-weight, Maintains $57.00 PT",2013-12-19 06:44:00-05:00,ABBV,neutral
9418.0,Enanta Pharmaceuticals Announces Additional Data from AbbVie's M13-393 Study to be Presented at Liver Meeting,2013-11-03 10:10:00-05:00,ABBV,neutral
9419.0,AbbVie Sees FY2013 EPS $3.11-3.13 vs $3.13 Est,2013-10-25 08:09:00-04:00,ABBV,neutral
9420.0,AbbVie Presents Phase II Data for HUMIRA in HS Patients,2013-10-03 06:16:00-04:00,ABBV,neutral
9421.0,AbbVie To Present Investigational Data From Phase II Hepatitis C Program At The Liver Meeting ,2013-10-01 10:02:00-04:00,ABBV,neutral
9422.0,"Argus Research Initiates Coverage on AbbVie at Buy, Announces $52.00 PT",2013-08-12 09:16:00-04:00,ABBV,neutral
9423.0,AbbVie Raises FY2013 EPS Guidance from $3.03-3.13 to $3.07-3.13 vs $3.11 Est,2013-07-26 07:54:00-04:00,ABBV,neutral
9424.0,AbbVie Reports Q2 EPS of $0.82 vs $0.79 Est; Revenue of $4.69B vs $4.54B Est,2013-07-26 07:53:00-04:00,ABBV,neutral
9425.0,"Bristol-Myers Squibb, AbbVie Announce Progression-Free Survival Data from Phase 2 Multiple Myeloma Study ",2013-06-15 11:51:00-04:00,ABBV,neutral
9426.0,AbbVie Announces Positive Results from Concerto Trial,2013-06-13 05:55:00-04:00,ABBV,positive
9427.0,"Jefferies Maintains Buy on AbbVie, Lowers PT to $51.00",2013-06-07 07:48:00-04:00,ABBV,negative
9428.0,"Jefferies Maintains Buy on AbbVie, Raises PT to $54.00",2013-05-28 08:25:00-04:00,ABBV,neutral
9429.0,Cowen & Company Initiates Coverage on AbbVie at Outperform,2013-05-15 08:49:00-04:00,ABBV,neutral
9430.0,"BMO Capital Maintains Market Perform on AbbVie, Raises PT to $47.00",2013-04-29 08:41:00-04:00,ABBV,neutral
9431.0,AbbVie Reports FY EPS of $0.68 vs $0.67 Est,2013-04-26 07:51:00-04:00,ABBV,neutral
9432.0,"Morgan Stanley Upgrades AbbVie to Overweight, Raises PT to $49.00",2013-04-22 06:15:00-04:00,ABBV,negative
9433.0,"UBS Maintains Neutral on AbbVie, Raises PT to $40.00",2013-04-10 09:41:00-04:00,ABBV,neutral
9434.0,"Jefferies Maintains Buy on AbbVie, Raises PT to $50.00",2013-04-10 07:45:00-04:00,ABBV,neutral
9435.0,"Goldman Sachs Maintains Buy on AbbVie, Raises PT to $45.00",2013-04-09 08:08:00-04:00,ABBV,neutral
9436.0,"BMO Capital Maintains Market Perform on AbbVie, Raises PT to $43.00",2013-04-05 07:40:00-04:00,ABBV,neutral
9437.0,"BMO Capital Downgrades AbbVie to Market Perform, Raises PT to $42.00",2013-04-01 08:55:00-04:00,ABBV,neutral
9438.0,"Bank of America Maintains Buy on AbbVie, Raises PO to $42.00",2013-03-11 08:06:00-04:00,ABBV,negative
9439.0,"AbbVie Announces $1.5B Buyback Plan, Declares $0.40/Share Dividend",2013-02-15 09:02:00-05:00,ABBV,neutral
9440.0,UPDATE: Credit Suisse Initiates AbbVie at Neutral on Humira Dependence,2013-02-07 10:38:00-05:00,ABBV,positive
9441.0,Perrigo Confirms FDA Approval for Generic AbbVie Product,2013-02-05 13:30:00-05:00,ABBV,positive
9442.0,UPDATE: Jefferies Raises PT to $45 on AbbVie on Pipeline Visibility,2013-02-04 12:13:00-05:00,ABBV,neutral
9443.0,Abbvie Says Not Planning Major Share Buybacks; Best Way to Deliver Value is to Boost Dividend,2013-01-30 09:53:00-05:00,ABBV,positive
9444.0,AbbVie Sees Q1 Adj-EPS $0.64-0.66 vs $0.69 Est,2013-01-30 09:34:00-05:00,ABBV,neutral
9445.0,AbbVie Sees FY2013 EPS $3.03-3.13 vs $3.08 Est,2013-01-30 07:46:00-05:00,ABBV,neutral
9446.0,"UPDATE: Jefferies Initiates AbbVie at Buy on Growth Outlook, High Yield  ",2013-01-16 08:30:00-05:00,ABBV,positive
9447.0,Benzinga's Top Initiations,2013-01-16 07:30:00-05:00,ABBV,positive
9448.0,US Stock Futures Edge Lower; Euro Drops Versus Dollar,2013-01-07 06:15:00-05:00,ABBV,negative
9449.0,"Stocks To Watch For January 7, 2013",2013-01-07 02:50:00-05:00,ABBV,neutral
9450.0,AbbVie Declares Inaugural Dividend of $0.40/Share,2013-01-04 19:59:00-05:00,ABBV,neutral
9451.0,"AbbVie Declares First-Ever Qtr. Dividend, $0.40/Share",2013-01-04 17:39:00-05:00,ABBV,neutral
9452.0,"UPDATE: Bank of America Merrill Lynch Initiates Coverage on AbbVie with Buy Rating, $40 PT",2013-01-04 08:38:00-05:00,ABBV,neutral
9453.0,UPDATE: Morgan Stanley Initiates AbbVie at Equal-Weight; Heavy Reliance on Humira  ,2013-01-03 13:42:00-05:00,ABBV,neutral
9454.0,Three Actionable Trading Ideas Right Now,2013-01-03 08:00:00-05:00,ABBV,neutral
9455.0,"UPDATE: BMO Capital Markets Initiates AbbVie at Outperform on Yield, Humira Support  ",2013-01-02 12:57:00-05:00,ABBV,positive
9456.0,"Abbott Spin-Off AbbVie Open for Trade, Shares Now Around $34.70",2013-01-02 09:39:00-05:00,ABBV,positive
9457.0,"UPDATE: J.P. Morgan Initiates Coverage on AbbVie with Neutral Rating, $38 PT",2013-01-02 08:56:00-05:00,ABBV,neutral
